Paola Guglielmelli

Scopus Publications

The Role and Impact of Non-driver Gene Mutations in Myelofibrosis
Valentina Boldrini, Paola Guglielmelli, Alessandro M. Vannucchi
Current Hematologic Malignancy Reports, 2026
Purpose of the Review Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) characterized by splenomegaly, constitutional symptoms, bone marrow fibrosis and potential progression to a blast phase. This review provides a comprehensive overview of the current molecular landscape of MF beyond canonical driver mutations ( JAK2 , MPL or CALR) , emphasizing insights gained from murine models that served as valuable tools for understanding disease mechanisms. Recent Findings High-throughput next-generation sequencing (NGS) has markedly enhanced our understanding of the molecular basis of MF, identifying numerous mutations beyond the canonical driver genes JAK2 , MPL , and CALR , which are present in about 80% of patients. Additional mutations affect genes involved in DNA methylation ( TET2 , DNMT3A , IDH1 , IDH2 ), histone modification ( ASXL1 , EZH2 ), mRNA splicing ( SF3B1 , SRSF2 , U2AF1 , ZRSR2 ), signaling pathways ( CBL , NRAS , KRAS ), and key transcription factors ( RUNX1 , NFE2 , TP53 ). The presence and combination of these alterations influence clinical presentation, prognosis, and therapeutic response. Summary This review offers an updated synthesis of the evolving molecular landscape of MF, highlighting how the intricate interplay among genetic alterations has deepened our understanding of disease heterogeneity, allowing refined risk stratification and therapeutic planning. Advances emerging from molecular research and experimental models are progressively translating into clinical practice, promoting more personalized and targeted approaches to the management of MF.
Understanding Triple Negative Myeloproliferative Neoplasms and Identifying Molecular Drivers
Valentina Boldrini, Giuseppe G. Loscocco, Paola Guglielmelli, Naseema Gangat, Alessandro M. Vannucchi, Ayalew Tefferi
Current Hematologic Malignancy Reports, 2026
Genomic structural variations contribute to inform prognosis in patients with cytogenetically normal acute myeloid leukemia
Niccolò Bartalucci, Francesco Mannelli, Danilo Tarantino, Alessio Enderti, Simone Romagnoli, Daniele Colazzo, Barbara Scappini, Giacomo Gianfaldoni, Matteo Piccini, Leonardo Signori, Fiorenza Irushani, Silvia Salmoiraghi, Tiziana Ottone, Alfonso Piciocchi, Margherita Vannucchi, Maria Chiara Siciliano, Roberto Boccacci, Silvia Orsi, Alessia Civini, Paola Fazi, Raffaella Santi, Marco Vignetti, Stefania Bortoluzzi, Alberto Bosi, Adriano Venditti, Alessandro Rambaldi, Maria Teresa Voso, Paola Guglielmelli, Alessandro M. Vannucchi
Blood Cancer Journal, 2026
Cytogenetic and genomic profiling of acute myeloid leukemia (AML) guides personalized treatment according to ELN2022 recommendations. However, marked outcome variability persists among cytogenetically normal (CN-) patients, representing an unmet clinical need. We used long-read whole-genome sequencing to interrogate the prognostic significance of structural variations (SVs) in a prospective cohort of 162 intensively treated CN-AML patients. After stringent filtering, we identified 5 somatic SVs associated with shorter overall survival (OS) (HR:4.18, p < 0.001) and event-free survival (EFS) (HR:3.59, p < 0.001) in 13% of the patients. Results were validated in a real-world cohort of 149 CN-AML, using target assays. These high-risk SVs (HRVs) operationally defined a “very high-risk” category in the framework of ELN2022, overall resulting in more accurate OS prediction. HRVs were independent of most frequent mutations, particularly FLT3ITD and NPM1mut. Among the latter patients, HRVs independently predicted shorter OS (8.2 months versus not-reached; p < 0.001), EFS (3.5 versus 25.7 months; p < 0.001), and lower complete response rates (66.7% versus 90.1%; p < 0.005). Finally, we provided evidence of transcriptional deregulation of SV-related genes in primary samples and engineered cell models. Current findings support the value of SVs for refining risk stratification in CN-AML, by identifying patients at exceedingly dismal outcome who might benefit from personalized approaches.
Autoimmune and Inflammatory Diseases in Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcomes and Comorbidities
Giuseppe G. Loscocco, Fnu Aperna, Moazah Iftikhar, Priyansh Faldu, Masooma S. Rana, Animesh Pardanani, Paola Guglielmelli, Alessandro M. Vannucchi, Naseema Gangat, Ayalew Tefferi
American Journal of Hematology, 2026
Polycythemia vera (PV) and essential thrombocythemia (ET) are chronic Philadelphia chromosome negative myeloproliferative neoplasms (MPN) characterized by clonal hematopoiesis, thrombotic risk, and variable disease evolution [1, 2]. Increasing evidence supports a role for immune dysregulation and inflammatory pathways in disease development and clinical heterogeneity, although their clinical implications remain incompletely defined [3]. Epidemiological studies have reported an association between prior autoimmune diseases and an increased risk of developing MPN [4]. Autoimmune or inflammatory diseases (AID) have also been described in approximately 6%–8% of patients with MPN, with heterogeneous effects on clinical features and survival across cohorts [5, 6]. However, the clinical burden of AID in patients specifically affected by PV and ET, particularly concerning disease outcomes and comorbidity profiles, remains poorly defined. We therefore evaluated the prevalence of AID in a large cohort of patients with PV and ET and assessed their association with disease outcomes and comorbidities. Institutional review board approval was obtained from the Mayo Clinic, Rochester, MN, USA, for retrospective data collection in accordance with the Declaration of Helsinki. The study included consecutive patients with PV and ET evaluated between 1970 and 2024 and diagnosed according to the 2022 International Consensus Classification criteria [7]. AID were defined according to established disease-specific clinical and serologic criteria. Clinical and laboratory variables were collected at diagnosis or first referral. Thrombotic events were confirmed by imaging studies and classified as arterial or venous; AID, cancers, and thrombotic events were categorized as occurring before/at or after MPN diagnosis using a ≥ 3 month interval. Overall survival was estimated using the Kaplan–Meier method and compared using the log-rank test. Competing-risk analyses were performed for thrombosis, leukemic transformation, myelofibrosis progression, second cancer, and incident AID using Fine–Gray regression models. Categorical variables were compared using the chi-square or Fisher's exact test, and continuous variables using the Mann–Whitney U test. Statistical analyses were performed using SPSS, JMP, and R software. Among 1968 patients with polycythemia vera (PV) or essential thrombocythemia (ET), 121 (6%) had a history of AID before/at the time of MPN diagnosis (Table 1). Compared with patients without AID, those with prior AID were older (median age 62 vs. 60 years, p = 0.016), more frequently female (69% vs. 55%, p = 0.002), and less likely to have PV (40% vs. 52%, p = 0.011). Hemoglobin levels were significantly lower in patients with AID (median 14.9 vs. 16 g/dL; p = 0.003), while platelet and leukocyte counts were similar between groups. A history of venous thrombosis at or prior to diagnosis was more frequent among patients with AID (18% vs. 12%, p = 0.046), whereas arterial thrombosis rates were comparable. Patients with previous AID more frequently had a history of other malignancies before/at MPN diagnosis (25% vs. 14%, p = 0.001), including when non-melanoma skin cancers (NMSC) were excluded (18% vs. 10%, p = 0.006). Additionally, the occurrence of subsequent AID during follow-up was more common among patients with prior AID (6% vs. 2%, p = 0.005). Among the 121 patients with AID before/at MPN diagnosis, 48 (40%) had PV and 73 (60%) had ET. Patients with PV were older (median 65 vs. 59 years, p = 0.043) and females were more common among ET cases (78% vs. 56%, p = 0.011). As expected, PV patients displayed higher hemoglobin levels, leukocyte counts, and neutrophil counts, while ET patients had higher platelet counts. Fibrotic progression was more frequent among PV cases (17% vs. 3%, p = 0.006), whereas leukemic transformation rates were low and comparable (Table S1). The spectrum of AID observed before/at and after MPN diagnosis is detailed in Figure 1A. The most frequently observed conditions included autoimmune dysthyroidism, rheumatoid arthritis, psoriasis, inflammatory bowel disease, and polymyalgia rheumatica. Kaplan–Meier analysis showed no significant difference in survival between patients with and without prior AID (log-rank p = 0.09, Figure 1B). In univariate analysis, prior AID showed a borderline association with inferior OS (HR 1.36, 95% CI 0.96–1.94, p = 0.087). After adjustment for sex, age, PV phenotype, and JAK2 mutation status, the association remained borderline and moved closer to statistical significance (HR 1.42, p = 0.054). Male sex (HR 1.50, 95% CI 1.27–1.77, p < 0.001) and increasing age (per 10 years, HR 2.43, 95% CI 2.25–2.62, p < 0.001) were independently associated with inferior survival, whereas PV (HR 1.15, p = 0.16) and JAK2 mutation status (HR 1.14, p = 0.34) were not significantly associated. To explore potential heterogeneity across AID, patients with prior AID were further stratified into two predefined categories based on the predominant clinical phenotype and anticipated degree of systemic inflammatory burden, distinguishing inflammatory arthritis, vasculitis, or unclassified AID from predominantly organ-specific, connective tissue, or inflammatory dermatosis conditions (Figure S1). In univariate analysis, patients with inflammatory arthritis, vasculitis, or unclassified AID exhibited significantly inferior survival compared with patients without AID (HR 1.89, 95% CI 1.13–3.16; p = 0.015), whereas those with organ-specific, connective tissue, or inflammatory dermatosis AID showed no significant difference (HR 1.10, 95% CI 0.69–1.77; p = 0.679). After multivariable adjustment, inflammatory arthritis/vasculitis/unclassified AID remained significantly associated with inferior survival (HR 1.64, 95% CI 1.01–2.70; p = 0.040), whereas organ-specific/connective tissue/inflammatory dermatosis AID showed no significant association (HR 1.29, 95% CI 0.80–2.08; p = 0.294). The cumulative incidence of major clinical outcomes after MPN diagnosis was assessed using competing-risk analysis (Figure S2). Prior AID was not significantly associated with MF progression (Gray test p = 0.20), AML progression (p = 0.52), venous (p = 0.49), or arterial thrombosis (p = 0.86). Conversely, a history of AID was associated with an increased risk of SC (Gray test p < 0.001, sHR 1.57, p = 0.015, Figure 2A). This association remained significant after excluding non-melanoma skin cancers (NMSC) (sHR 1.70, p = 0.022), whereas after excluding both NMSC and hematologic malignancies, only a non-significant trend was observed (sHR 1.52, p = 0.12). In the multivariable model including all cancers, prior AID was not independently associated with SC risk (sHR 1.31, 95% CI 0.88–1.96, p = 0.183) after adjustment for sex, age, PV versus ET, JAK2 mutation status, prior cancer history, hyperlipidemia, hypertension, and arterial thrombosis. Of interest, after exclusion of NMSC, prior AID showed a trend toward increased SC risk (sHR 1.50, 95% CI 0.93–2.42, p = 0.094). This association was no longer observed in the most restrictive model excluding both NMSC and hematologic malignancies (sHR 1.35, 95% CI 0.79–2.32, p = 0.276). The occurrence of incident AID after MPN diagnosis was subsequently analyzed using competing-risk methods. The cumulative incidence of AID was significantly higher among patients with prior AID compared with those without (Gray test p < 0.001, Figure 2B). In univariate analysis, prior AID (sHR 3.89, p = 0.001) and female sex (sHR 2.63, p = 0.007) were significantly associated with an increased risk of incident AID. Hypertension showed a borderline association (sHR 1.74; p = 0.095), whereas no other clinical, hematologic, or molecular variables were significantly associated (Table S2). In the multivariable model (Figure 2C), prior AID (sHR 3.03, p = 0.012), female sex (sHR 2.39, p = 0.015), and hypertension (sHR 2.18, p = 0.024) remained independently associated with an increased risk of incident AID. In this large cohort of patients with PV and ET, AID were identified in 6% of cases and were associated with a distinct clinical and comorbidity profile. Patients with prior AID were more frequently female, slightly older, and more likely to have a history of venous thrombosis and prior malignancy. These findings are consistent with previous epidemiologic studies supporting shared inflammatory and immune-mediated mechanisms across AID and myeloid neoplasia, as well as the increased risk of MPN development among patients with pre-existing AID [4, 6, 8]. Although prior AID was not significantly associated with fibrotic or leukemic progression, nor with arterial or venous thrombosis during follow-up, a borderline association with inferior survival was observed and persisted after multivariable adjustment. Exploratory analyses highlighted heterogeneity across autoimmune phenotypes, with selected AID categories demonstrating a sustained association with inferior survival [9]. Collectively, these findings support the concept that immune dysregulation and chronic inflammatory burden contribute to disease heterogeneity in MPN, influencing long-term outcomes beyond classical disease-related risk factors [3]. A history of AID was associated with an increased risk of SC in unadjusted analyses, particularly after exclusion of NMSC, although this association was attenuated after multivariable adjustment. This finding suggests that part of the observed risk may be explained by coexisting clinical factors, including prior malignancy history and cardiometabolic comorbidities, while remaining consistent with prior observations linking chronic immune dysregulation with carcinogenesis across multiple disease settings [5, 10-12]. A particularly relevant observation was the significantly increased risk of incident AID after MPN diagnosis among patients with prior AID, independent of sex, age, and hypertension. This finding aligns with the well-recognized phenomenon of polyautoimmunity, whereby individuals with one autoimmune disease have an increased risk of developing additional immune-mediated conditions over time [13, 14]. Several limitations should be acknowledged. The retrospective design introduces potential selection and ascertainment biases, and the relatively low number of specific outcomes may have limited statistical power in subgroup analyses. In addition, treatment heterogeneity across the long study period was not specifically accounted for and may have influenced clinical outcomes. Furthermore, the intrinsic heterogeneity of AID, encompassing conditions with distinct pathophysiologic mechanisms and clinical trajectories, limited the ability to evaluate outcomes for individual AID entities and required grouping into broader categories, which may have diluted subtype-specific associations. Despite these limitations, the large sample size, extended follow-up, and use of competing-risk methodology strengthen the robustness of the findings. G.G.L., N.G., and A.T. conceived and designed the study. G.G.L., F.A., M.I., P.F., M.S.R., and N.G. collected the data. G.G.L. performed statistical analyses. G.G.L. drafted the manuscript. P.G., A.M.V., A.P., N.G., and A.T. reviewed and edited the manuscript. The authors declare no conflicts of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request. TABLE S1: Clinical, laboratory, and genetic characteristics at diagnosis and during follow-up in 121 patients with autoimmune or inflammatory disease before/at MPN diagnosis, stratified by polycythemia vera and essential thrombocythemia. TABLE S2: Univariate Fine–Gray regression analysis for risk of incident autoimmune or inflammatory diseases (AID) after MPN diagnosis. FIGURE S1: Overall survival according to autoimmune or inflammatory disease (AID) category. Kaplan–Meier curves comparing overall survival among patients with arthritis/vasculitis/unclassified AID, organ-specific/connective tissue disease (CTD)/dermatosis, and patients without prior AID. FIGURE S2: Cumulative incidence of major disease outcomes according to prior autoimmune or inflammatory disease (AID). Cumulative incidence curves comparing patients with prior AID versus no prior AID for (A) myelofibrosis (MF) progression, (B) acute myeloid leukemia (AML) progression, (C) venous thrombosis, and (D) arterial thrombosis. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Clinical Experience With Venetoclax-Based Combinations for Relapsed/Refractory or MRD-Positive NPM1-Mutated Acute Myeloid Leukemia
Matteo Piccini, Naseema Gangat, Francesco Mannelli, Barbara Scappini, Gaia Ciolli, Francesca Crupi, Andrea Pasquini, Jessica Caroprese, Giorgio Cannetti, Chiara Lucarelli, Silvia Querceto, Giada Rotunno, Fabiana Pancani, Niccolò Bartalucci, Paola Guglielmelli, Ayalew Tefferi, Alessandro Maria Vannucchi
American Journal of Hematology, 2026
NPM1 mutations occur in ~30% of acute myeloid leukemia (AML) [1] and define a distinct entity according on current WHO and ICC classification [2, 3]. NPM1mut AML shows heterogeneous clinical behavior: some patients respond well to chemotherapy with rapid measurable residual disease (MRD) clearance, while others experience primary refractoriness or early relapse. Co-mutations, particularly FLT3-ITD, contribute to this variability [4]. While first-line treatment of NPM1mut AML is well established [1], optimal management of relapsed/refractory (R/R) disease remains uncertain. Furthermore, in case of primary refractory or early relapsing patients, chemoresistance represents an issue [5]. For patients treated with curative intent, salvage chemotherapy followed by allogeneic stem cell transplantation (ASCT) is standard approach, although such regimens are burdened by toxicities that delay or prevent ASCT in some cases. In elderly and HSCT ineligible patients, therapeutic options are limited. Recently, favorable toxicity profile and efficacy of venetoclax (VEN) in combination with hypomethylating agents (HMAs) or low-dose cytarabine (LDAC) in NPM1mut AML was reported in first line [6, 7] and the R/R setting [8-10]. Moreover, considering the evolving therapeutic scenario, the role of MRD-directed intervention in NPM1mut AML, based on early detection of impending relapse at the molecular level, is unclear [11]. We retrospectively analyzed 58 adult patients with R/R or MRD-positive NPM1mut AML treated with VEN-based approaches at Careggi University Hospital, Florence (Italy) (n = 28) and Mayo Clinic, Rochester, Minnesota (US) (n = 30) between 2018 and 2025. Median age was 61.5 years (26–83); 31/58 (53.4%) patients were older than 60 years. Median follow-up duration was 26.2 months. Most patients (n = 43, 74%) were treated for relapsed disease (1st relapse, n = 35; subsequent relapse, n = 8), that in most cases occurred after CR of short duration (< 6 months, n = 27; 6–12 months, n = 9; > 12 months, n = 5; unknown, n = 2). Three patients were primary refractory. Twelve patients received VEN-based treatment as an MRD-directed approach (MRD persistence after frontline chemotherapy, n = 8; MRD relapse, n = 4). Overall, 37 patients (64%) were treated with intention-to-transplant (ITT); ultimately, 29/37 patients (78%) were able to proceed to ASCT. VEN-based treatments were mainly represented by VEN combined with HMA (n = 47/58; 81%; azacitidine, n = 30; decitabine, n = 17); other combinations including FLT3 inhibitors (FLT3i), menin inhibitors, or intensive chemotherapy. Full details of patients' characteristics and treatment regimens can be found in Table S1. Most frequently detected co-mutations were FLT3-ITDs (n = 24; 41%; median allelic ratio 0.425 (0.002–1.500)), DNMT3A (n = 23; 39%), IDH1 and IDH2 (n = 17; 31%), RAS pathway (n = 14; 24%), and FLT3-TKD (n = 6; 10%) (Figure 1 and Table S2). A total of 282 cycles were administered (with hospitalization, n = 46; 16.3%); median cycle number per patient was 4 for non-ASCT patients and 3 for HSCT recipients. Reasons for treatment discontinuation were ASCT (n = 22), treatment failure (n = 20), excessive myelotoxicity (n = 5), unknown reasons (n = 4), medical decision (n = 3), infection (n = 1), death due to unrelated cause (n = 1). At the time of data cut-off, two patients were still receiving treatment. Overt R/R cohort: composite CR rate (CCR; CR + CR with incomplete counts recovery) was 65.2% (30/46), with 17/46 (36.9%) patients achieving CR and 13/46 (28.3%) CRi status. About 70% of complete responders achieved MRD negativity in bone marrow (BM) and/or peripheral blood (PB) by RT-qPCR (or flow cytometry, in case of noncanonical mutant NPM1 transcripts). Best response occurred early during treatment (cycle 1, n = 20; cycle 2, n = 4; cycle 3, 4, and 6, n = 1; unknown, n = 3). No genetic biomarker (including aberrant karyotype, FLT3-ITD status, IDH1/2 status, RAS pathway mutations) or prior exposure to HMA or FLT3i influenced CR probability (Table S3). Patients with FLT3 mutation (ITD or TKD) had a CCR of 63.6% (14/22; CR, n = 6; CRi, n = 8); restricting the analysis to FLT3-ITD cases, CCR was 55.5% (10/18; CR, n = 2/10; CRi, n = 8/10). Prior FLT3i exposure did not reduce CCR in FLT3-mutated patients. Eighteen of 25 (72%) patients treated with ITT were able to proceed to ASCT. Median OS and EFS was 20.7 and 13 months, respectively (Figures 2 and 3). IDH1 or IDH2 mutation was associated with longer, though not statistically significant, EFS (45.7 vs. 9.7 months, p = 0.137) and OS (24.5 vs. 9.5 months; p = 0.064). Conversely, FLT3-ITD positivity was associated with shorter EFS (9.5 vs. 13.9 months) and OS (9.5 vs. 24.5 months). Patients undergoing had significantly longer EFS (26.8 vs. 5.7 months; p = 0.048) and OS (median not reached vs. 9.5 months; p = 0.013). A survival plateau for both EFS and OS was observed, with seven patients experiencing long-term survival at data cut (five off treatment). In multivariate analysis, both IDH1/2 mutation and ASCT were independently associated with improved outcomes. IDH1/2 mutation was associated with a > three-fold reduction in risk of death (OS: HR 0.324; 95% CI, 0.108–0.968; p = 0.043) and a nonsignificant reduction in event risk (EFS: HR 0.400; 95% CI, 0.146–1.097; p = 0.075). ASCT was significantly associated with improved OS (HR: 0.267; 95% CI: 0.103–0.690; p = 0.006) and EFS (HR: 0.371; 95% CI: 0.103–0.885; p = 0.025) (Table S4). MRD relapse/persistence cohort: All patients achieved complete MRD clearance by RT-qPCR, including 7 with FLT3 mutations (FLT3-TKD, n = 1; FLT3-ITD, n = 6). Best response occurred at cycle 1 in 5 patients, cycle 2 in 3, cycle 3 in 3, and cycle 4 in 1. All patients were successfully bridged to ASCT, except for a 57-year-old woman diagnosed with end-stage cholangiocarcinoma (Table S3). Median OS and EFS were not reached (Figure 3), and most OS events were due to transplant-related mortality. The safety profile was consistent with previous reports, with no treatment-related deaths. Nonhematologic adverse events are reported in Table S5. Notably, in the MRD relapse/persistence cohort, VEN-based regimens (VEN-AZA, n = 9; VEN-AZA + ziftomenib, n = 2; VEN + gilteritinib, n = 1) were particularly well tolerated, with cytopenias (mainly neutropenia) as the most frequent treatment-related AE and only one case of G3 febrile neutropenia. To our knowledge, this represents one of the largest series evaluating outcomes of R/R and MRD positive NPM1mut AML patients treated with VEN-based combinations. The observed CCR rate is comparable to that reported for conventional salvage regimens in R/R AML patients [12], including NPM1mut cases, despite most patients in our cohort would being ineligible for intensive chemotherapy due to age or comorbidities and having short prior CR duration, a setting typically associated with poor outcomes. Although the study was not powered to assess the impact of co-mutations on CR achievement and survival, improved outcomes were observed in patients with IDH1 or IDH2 mutations, consistent with previous reports [7, 9, 10]. In FLT3mut patients, while FLT3 inhibitor-based regimens remain preferred, VEN-based approaches may represent a potential option. Notably, patients treated for MRD relapse or persistence achieved high MRD clearance and favorable survival. The tolerability and activity of VEN-based regimens support their potential role in MRD-directed therapy, currently being investigated in a phase II GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) trial (NCT04867928). The favorable toxicity profile of VEN-based regimens may offer an advantage over conventional salvage chemotherapy, particularly as bridge-to-transplant in R/R NPM1mut AML. Interestingly, the durable CRs were observed in some patients even without ASCT, warranting further investigation. This work received funding from “Fondo Zottola”, University of Florence. This study was reviewed and approved by the Institutional Review Board (Comitato Etico Area Vasta Centro—CEAVC). Written informed consent was obtained by patients according to the Declaration of Helsinki. M.P.: Speaker bureau AbbVie Pharmaceuticals, Astellas, Astrazeneca, SERB, Amgen, Incyte. N.G.: Advisory Board for DISC Medicine and Agios. F.M.: Speaker bureau Blueprint, Novartis, Abbvie, Servier, GSK, Astellas. A.M.V.: honoraria from AbbVie, Novartis, Blueprint, GSK. The data that support the findings of this study are available from the corresponding author upon reasonable request. Table S1: Clinical and demographic characteristics of the study population. CR, complete remission; FLT3i, FLT3 inhibitor; HSCT, hematopoietic stem cell transplantation; ITD, internal tandem duplication; ITT, intention-to-transplant; MRD, minimal residual disease; TKD, tyrosine kinase domain; VEN, venetoclax. Table S2: Cytogenetic and molecular characteristics of the whole patient population. Full details regarding co-mutations can be found in Figure 1. Table S3: Response rates and kinetics with VEN-based regimens and HSCT bridging data in relapsed/refractory and MRD-positive patients sub-cohorts. CCR, composite complete remission; CR, complete remission; CRi, complete remission with incomplete counts recovery; FLT3i, FLT3 inhibitor; HMA, hypomethylating agent; HSCT, hematopoietic stem cell transplantation; ITT, intention-to-transplant; MRD, minimal residual disease. Table S4: Survival data according to relevant clinical and molecular covariates. EFS, event-free survival. HSCT, hematopoietic stem cell transplantation. HR, hazard ratio. OS, overall survival. Table S5: Nonhematological adverse events (whole cohort). Grading according to common terminology criteria for adverse events (CTCAE) version 5.0. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Describing the use of ruxolitinib for the treatment of myelofibrosis: a plain language summary of the ROMEI early study results
Massimo Breccia, Paola Guglielmelli, Chiara Castiglioni, Francesca Palandri, Francesco Passamonti
Future Oncology London England, 2026
What is this summary about? This plain language summary describes the first results obtained from the ROMEI study. In this study, researchers want to learn how doctors in Italy use ruxolitinib to treat people with myelofibrosis, a rare type of blood cancer. It also looks at how ruxolitinib affects the symptoms and overall health of participants. What are the key takeaways? Out of 306 participants, 57% received the expected dose of ruxolitinib, based on their blood test results. Conversely, 43% started with a lower dose than expected, even though their blood test results would have allowed a higher dose. Before the start of the study, people who received the expected dose of ruxolitinib (the ‘AsEx group’) were generally younger and showed better blood test results than participants who received a lower-than-expected dose (the ‘LtEx group’). During the first 12 months of the treatment, participants in the AsEx group were treated with ruxolitinib for a longer time with fewer interruptions compared to participants in the LtEx group. They also felt better sooner and had a greater, faster reduction in the size of their spleen. Fewer people in the AsEx group died compared to the LtEx group. What were the main conclusions reported by the researchers? Patients who received the expected dose of ruxolitinib showed greater improvements in their health compared to those who received a lower dose. Some physicians started with lower doses for older or more frail patients. However, in this study, starting at a lower dose did not show additional advantages. What do the results mean and why does it matter? These results show how important it is to start ruxolitinib at the right dose, based on each person’s blood test results. Starting at the right dose can help people with myelofibrosis get the best possible results from treatment, such as faster relief from symptoms, reduction of spleen size, and possibly a longer life.
Artificial intelligence differentiates prefibrotic primary myelofibrosis with thrombocytosis from essential thrombocythemia using digitized bone marrow biopsy images
Andrew Srisuwananukorn, Giuseppe Gaetano Loscocco, James M. Dolezal, Andrew T. Kuykendall, Raffaella Santi, Ling Zhang, Avani M. Singh, Paola Guglielmelli, Alessandro Maria Vannucchi, Mohamed E. Salama, Alexander T. Pearson, Ronald Hoffman
Leukemia, 2026
Prefibrotic primary myelofibrosis (prePMF) and essential thrombocythemia (ET) are distinct myeloproliferative neoplasms (MPNs) with overlapping clinical features, often leading to diagnostic uncertainty. We developed an artificial intelligence (AI) framework with human interpretability to distinguish prePMF from ET using digitized hematoxylin and eosin-stained bone marrow biopsy (BMB) slides. Trained on an initial cohort of MPN patients with thrombocytosis, the AI model achieved an AUROC of 0.89 and accuracy of 92.3%. To assess the image features guiding predictions, we generated synthetic images which potentially exaggerate disease-specific morphologies. In a blinded survey, hematopathologists reviewed both real and AI-generated images. While human experts frequently agreed with AI predictions on diagnosis with real images, diagnostic discordance reached up to 88% for AI-generated ET images despite being correctly predicted by AI. We further quantified marrow cellularity and adiposity in the real and generated images, which revealed a higher proportion of fat content in all ET images (42.0%) compared to prePMF (28.9%). These findings suggest that AI can utilize morphological cues distinct from current established diagnostic criteria, such as proportion of adiposity to distinguish types of MPNs. Thus, an AI-assisted diagnostic tool underscores the potential of AI to augment histopathologic evaluation and allow identification of more specific subpopulations of forms of MPNs.
APL-like subset within NPM1-mutated AML: A distinct immunophenotype correlating with early vascular complications
Francesco Mannelli, Francesca Crupi, Sara Bencini, Michaela Feuring, Gaia Ciolli, Matteo Piccini, Marco Frigeni, Raffaele Palmieri, Chiara Sartor, Barbara Scappini, Giacomo Gianfaldoni, Benedetta Peruzzi, Roberto Caporale, Antonio Scannella, Laura Fasano, Elisa Quinti, Andrea Pasquini, Jessica Caroprese, Leonardo Signori, Fabiana Pancani, Chiara Maccari, Tiziana Ottone, Daniela Spaeth, Antonio Curti, Maria Teresa Voso, Francesco Annunziato, Konstanze Döhner, Adriano Venditti, Francesco Buccisano, Alessandro Rambaldi, Paola Guglielmelli, Hartmut Döhner, Alessandro M. Vannucchi
Hemasphere, 2026
Among NPM1 ‐mutated acute myeloid leukemia (AML) ( NPM1 mut ), a distinct subtype has been described with an immunophenotypic profile resembling acute promyelocytic leukemia (APL‐like). In this retrospective multicenter study including 384 NPM1 mut AML patients, we identified 95 (24.7%) cases exhibiting an APL‐like immunophenotype. This subset was characterized by significant abnormalities in coagulopathy markers (D‐dimer, D‐dimer/fibrinogen ratio, and disseminated intravascular coagulation [DIC] score). The cumulative incidence of vascular events at 30 days was significantly higher in the APL‐like group compared to the non‐APL‐like group (30.5% vs. 10.1%, P < 0.001). Notably, a higher cumulative incidence of early death due to vascular complications (within 30 days) was observed in the APL‐like group (6.3% vs. 0.35% in controls; P = 0.00015). In multivariate analysis, the APL‐like immunophenotype was the only significant factor associated with vascular‐related early death (hazard ratio [HR] = 19, P = 0.0063). There was a significantly higher rate of IDH1/2 mutations in APL‐like (68.3%) compared to non‐APL‐like (18.3%, P < 0.001) cases. We validated these clinical and molecular findings in an independent validation cohort of 302 NPM1 mut patients enrolled in the acute myeloid leukemia study group (AMLSG) 09‐09 clinical trial, which included the administration of all‐trans retinoic acid (ATRA) to all patients and a randomization for gemtuzumab ozogamicin. In this cohort, the APL‐like immunophenotype was associated with events occurring within the first 15 days but did not influence mortality, likely due to protocol‐driven patient selection. Our findings have important clinical implications that warrant the development of studies exploring disease‐tailored clinical measures to mitigate the risk of early vascular events, as in current APL management.
ONE HUNDRED SUSPECTED MYELOPROLIFERATIVE NEOPLASMS WITH A JAK2 V617F VARIANT ALLELE FREQUENCY <2%: CLINICAL, GENETIC AND HISTOPATHOLOGICAL CORRELATES
Giuseppe Gaetano Loscocco
Haematologica, 2026
Introduction. JAK2 V617F (JAK2) is the most frequent driver mutation in myeloproliferative neoplasms (MPN), but it was found in healthy individuals with clonal hematopoiesis of indeterminate potential (CHIP), though its role in CHIP remains debated (Leukemia 2021;35(9):2706-2709). We examined clinical, genetic, and morphological features in suspected MPN cases with JAK2 VAF <2%. Methods. We included 100 suspected MPN cases with JAK2 VAF <2% (2010–2025). After excluding secondary causes, patients were grouped as follows: erythrocytosis (n=35), thrombocytosis (n=47), and miscellaneous (n=18; detailed in Figure 1). All samples and data were collected at diagnosis. JAK2 VAF was assessed in granulocytes by dd-PCR (limit of detection 0.01%); BM biopsies were reviewed by R.S. and U.G. (Blood 2022; 140(11):1200-1228).Results. Overall, median age was 62 years, male 64%, median JAK2 VAF 0.22%. Median (range) leukocyte count was 7.6 x 109/L (5-30), hemoglobin 14.6 g/dL (9-19.5), hematocrit 43.5% (28-57), platelets 408x109/L (98-1450). Previous history of venous and arterial thrombosis in 10%/12%, respectively. No age differences among 3 groups (p=0.8), whereas patients with erythrocytosis were mostly male (91% vs. 42% vs. 67%, p<0.01), EPO value subnormal in only 1 case. Driver mutations other than JAK2 were documented in 33 patients: 24 CALR comprising type-1 (n=17), type-2 (n=5), atypical (n=2) and 9 MPL (7 at p.W515 and 2 at p.S505). Of note, double driver mutated cases constituted 68% of all those with thrombocytosis. Respective median VAF for CALR /MPL mutations were 34%/21%. Considering patients with thrombocytosis, those with JAK2 only vs. double mutated were mostly ET (93% vs. 60%, p=0.03), had lower platelets (546 vs. 845x109 /L, p<0.01), and higher JAK2 VAF (0.55 vs. 0.15%, p=0.04). Additional NGS mutations were reported in 24 (52%) cases, mostly, in miscellaneous group (75%, p=0.2); overall, the most represented were ASXL1 (13%), TET2 (7%), SH2B3 (7%), KIT (7%), DNMT3A (7%), NF1 (7%) mutations. 9% showed abnormal karyotypes (7 cases –Y, 1 case -22, 1 case +13), with similar distribution across the groups. Considering patients with erythrocytosis, BM histologic features were consistent with PV in 8 cases whereas the other 27 cases showed age-adjusted normal/focally increased cellularity, regular/mildly expanded erythroid lineage consistent with a diagnosis of MPN unclassifiable (MPN-U). Among patients with thrombocytosis and miscellaneous group, diagnosis are reported in Figure 1. Conclusions. This study underscores the significance of employing highly sensitive assays for the detection of JAK2, as well as emphasises the necessity of concurrent screening for CALR and MPL mutations in patients presenting with thrombocytosis and low JAK2 VAF. In those with erythrocytosis, early histopathological signs of MPN can be subtle, so integrating histopathology with clinical and genetic data is essential for an appropriate diagnosis.
MOLECULAR CHARACTERIZATION OF A COHORT OF PATIENTS WITH POLYCYTHEMIA VERA: A SINGLE-CENTER STUDY
Elena Nacca
Haematologica, 2026
Introduction. Polycythemia vera (PV) is a chronic myeloproliferative neoplasm mainly driven by JAK2 mutations. Additional myeloid gene mutations (MyMut) have been reported, sometimes with prognostic relevance, but the molecular landscape at diagnosis and its impact on disease phenotype or outcome remain unclear.Methods. We included patients (pts) with a diagnosis (dx) of PV according to WHO/ICC 2022 criteria with at least a DNA sample collected at dx or during the chronic phase in the absence of disease progression, and with comprehensive hematologic, clinical, and outcome data. Molecular and bioinformatic analyses were performed using a targeted NGS panel (SOPHiA DDM Myeloid Solution) on the SOPHiA DDM platform.Results. A total of 637 PV pts were analyzed, 355 (55.7%) were males with a median age of 61.3 years (range 14.4–91.8). 138 pts (21.7%) progressed to post-PV Myelofibrosis (MF), 15 (2.4%) to blast phase (BP) during the PV chronic phase, 222 (34.9%) pts had at least an event of thrombosis (138 (62.2%) at dx or within the 5 preceding years, and 109 (49.1%) during follow-up), including both arterial (n=121) and venous (n=125). Death occurred in 109 (17.1%). Almost all pts (99.4%) harbored a JAK2 mutation: JAK2 V617F in 625 (98.1%) cases and JAK2 exon 12 mutations in 8 (1.3%). 4 pts resulted JAK2 WT. Additionally, 11 pts (10 V617F, 1 exon 12) harbored a JAK2 mutation combined with a non-canonical JAK2 variant. Other MyMut were found in 283 pts (44.4%), with 8.9%, and 2.4% of pts harboring 2 or ≥3 mutations, respectively. JAK2-negative pts showed mutations in ASXL1 (n=1), DNMT3A (n=1) and ZRSR2 (n=1). The most frequently mutated genes (≥5 pts) were: TET2 (21.4%, mean VAF 23.9%), ASXL1 (12%, mean VAF 24.4%), DNMT3A (9.9%, mean VAF 17.8%).The most common co-mutation patterns were: 9.4% pts carried both TET2 and ASXL1 mutations, 8% TET2 and DNMT3A, 4.8% ASXL1 and EZH2, 5.8% ASXL1 and IDH2.Correlation analyses showed that the presence of at least 1 MyMut correlates with worst prognosis, as shown in Figure 1. In particular, genes more significantly associated with shortened overall survival (OS) were DNMT3A (p=0.012), TET2 (p<0.001) and U2AF1 (p=0.002). In addition, ASXL1 (p<0.001), and EZH2 (p=0,002) were associated with progression to secondary myelofibrosis –postPV, while DNMT3A (p<0.001) resulted inversely correlated with MF progression. Conclusions. These findings demonstrate that almost half of PV pts show a complex molecular landscape already at diagnosis, and that both survival and progression to MF may be influenced by the presence of additional mutations in myeloid-associated genes. Comprehensive molecular profiling at diagnosis may improve risk stratification and future prognostic models in PV.
JAK2 46/1 HAPLOTYPE AND JAK2 VARIANT ALLELIC FREQUENCY CORRELATE WITH THE DEVELOPMENT OF POLYCYTHEMIC PHENOTYPE IN JAK2-MUTATED ESSENTIAL THROMBOCYTEMIA PATIENTS
Giulio Capecchi
Haematologica, 2026
MOLECULAR RISK PROFILING IN MYELOPROLIFERATIVE NEOPLASMS BLAST PHASE (MPN-BP) TREATED WITH VENETOCLAX AND DECITABINE: A THREE-GENE SCORE FOR SURVIVAL PREDICTION
Francesca Crupi
Haematologica, 2026
DISCONTINUATION OF VENETOCLAX-BASED THERAPIES IN MOLECULARLY SELECTED PATIENTS WITH ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION
Gaia Ciolli
Haematologica, 2026
PRE-CLINICAL EFFICACY OF A NOVEL COMBINED PHARMACOLOGICAL APPROACH TARGETING JAK AND ERK IN A MYELOFIBROSIS MOUSE MODEL
Matteo Bertesi
Haematologica, 2026
SINGLE-CELL MULTI-OMICS UNRAVELS MOLECULAR AND CELLULAR PROGRAMS UNDERLYING RUXOLITINIB RESPONSE IN MYELOFIBROSIS
Chiara Carretta
Haematologica, 2026
CD9 DEFINES THE DISEASE-PROPAGATING HEMATOPOIETIC STEM CELL POPULATION IN MYELOFIBROSIS
Ruggiero Norfo
Haematologica, 2026
Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI)
Paola Guglielmelli, Massimo Breccia, Francesco Mendicino, Maurizio Martelli, Nicola Di Renzo, Giuseppe A. Palumbo, Monica Crugnola, Maurizio Musso, Silvia Sibilla, Paolo Sportoletti, Elisabetta Abruzzese, Stefana Impera, Alessandra Malato, Sergio Siragusa, Carmine Selleri, Fabrizio Pane, Bruno Martino, Alessandra Ricco, Angelo Gardellini, Anna Marina Liberati, Agostino Tafuri, Maria Langella, Marco Brociner, Paolo Ditonno, Domenico Pastore, Olga Mulas, Barbara Pocali, Marco De Gobbi, Erika Morsia, Giulia Benevolo, Elena Maria Elli, Valerio De Stefano, Antonietta Pia Falcone, Daniele Vallisa, Simona Tomassetti, Francesca Lunghi, Nicola Orofino, Giuseppe Carli, Tiziana Urbano, Alessandro Lucchesi, Marta Brunoventre, Massimiliano Bonifacio, Gianni Binotto, Francesco Cavazzini, Paola Ranalli, Alessandro Allegra, Barbara Anaclerico, Serena Mazzotta, Filippo Gherlinzoni, Mario Tiribelli, Chiara Castiglioni, Marina Landoni, Diletta Valsecchi, Michela Magnoli, Francesco Passamonti, Francesca Palandri
Hematological Oncology, 2026
The influence of patient engagement and self-efficacy on self-care in myeloproliferative neoplasms: A mediation analysis
Valentina Biagioli, Alessandro Inzoli, Antonella Barone, Alessandra Iurlo, Paola Guglielmelli, Francesca Palandri, Barbara Mora, Stefana Impera, Silvia Betti, Marco Santoro, Vittorio Rosti, Giovanni Barosi
European Journal of Oncology Nursing, 2026
A Novel, Ruxolitinib-Sensitive, CCDC6::JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera-Like, Myeloproliferative Neoplasm
Niccolò Bartalucci, Danilo Tarantino, Giuseppe G. Loscocco, Alessio Enderti, Daniele Colazzo, Raffaella Santi, Daniela Parrini, Manjola Balliu, Valentina Boldrini, Yasmine Abbassi, Elisabetta Pelo, Monia Marchetti, Paola Guglielmelli, Alessandro M. Vannucchi
American Journal of Hematology, 2026
Health Care Utilization Databases obtained from health system inform outcome for ruxolitinib treatment in patients with myelofibrosis
Barbara Mora, Matteo Franchi, Ludovica Margotto, Olivia Leoni, Daniela D'ippoliti, Emanuela Carloni, Ilaria Cozzi, Enrica Santelli, Fabrizio Gemmi, Claudia Szasz, Margherita Maffioli, Carmelo Gurnari, Enrico Attardi, Daniele Cattaneo, Marta Bortolotti, Nicola Stefano Fracchiolla, Alessandra Iurlo, Giovanni Corrao, Matteo Giovanni Della Porta, Alessandro Maria Vannucchi, Maria Teresa Voso, Paola Guglielmelli, Francesco Passamonti
Hemasphere, 2026
Distinct Longitudinal Patterns of Basal and Squamous Cell Carcinoma in Polycythemia Vera and Essential Thrombocythemia
Giuseppe G. Loscocco, Naseema Gangat, Paola Guglielmelli, Animesh Pardanani, Alessandro M. Vannucchi, Ayalew Tefferi
American Journal of Hematology, 2026
IMPROVING DIAGNOSTIC STANDARDIZATION IN MYELOPROLIFERATIVE NEOPLASMS: RESULTS FROM THE ITALIAN JAKNET PROGRAM
Francesca Gesullo
Haematologica, 2026
Genomic profiling for decision-making in post–polycythemia vera and post–essential thrombocythemia myelofibrosis
Barbara Mora, Francesca Palandri, Paola Guglielmelli, Andrew T. Kuykendall, Margherita Maffioli, Alessandra Iurlo, Valerio De Stefano, Silvia Salmoiraghi, Timothy Devos, Federico Itri, Francisco Cervantes, Jean-Jacques Kiladjian, Matteo G. Della Porta, Francesco Albano, Jason Gotlib, Giulia Benevolo, Marianna Caramella, Marco Ruggeri, Elisa Rumi, David M. Ross, Chiara Pessina, Ilaria Colugnat, Francesco Orsini, Giorgia Micucci, Giada Rotunno, Rami S. Komrokji, Daniele Cattaneo, Patrizia Chiusolo, Marta Bortolotti, Tiziano Barbui, Daniela Cilloni, Massimo Breccia, Giuseppe A Palumbo, Filippo Branzanti, Ludovica Margotto, Matteo Franchi, Alessandro M. Vannucchi, Francesco Passamonti
Blood, 2026
Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22/CD40
William J. Tapper, Ahmed A. Z. Dawoud, Joannah Score, Andrew J. Chase, E. Joanna Baxter, Joanne Ewing, Louise Wallis, Paola Guglielmelli, Dolors Colomer, Beatriz Bellosillo, Montse Gomez, Juan Carlos Hernández-Boluda, Carlos Besses, Francisco Cervantes, Steffen Koschmieder, Anthony R. Green, Andreas Reiter, Alessandro Vannucchi, Claire Harrison, Nicholas C. P. Cross
Blood, 2025
Combinatorial BCL2/BCL2L1 expression predicts clinical response to ruxolitinib in myelofibrosis
Giacomo Coltro, Viola Videschi, Francesca Gesullo, Federica Violi, Manjola Balliu, Alessandro M. Vannucchi, Paola Guglielmelli
Biomarker Research, 2025
Neutrophil-to-Lymphocyte ratio as surrogate for JAK2V617F suppression and event-free survival in polycythemia vera
Tiziano Barbui, Arianna Ghirardi, Victoria Empson, Francesca Fenili, Giuseppe Gaetano Loscocco, Annalisa Condorelli, Alessandra Iurlo, Daniele Cattaneo, Elena Rossi, Valerio De Stefano, Paola Guglielmelli, Christoph Klade, Heinz Gisslinger, Alessandro Rambaldi, Joseph M. Scandura, Alessandro Maria Vannucchi
Blood Cancer Journal, 2025
Combined MEK and JAK inhibition reduces osteopontin plasma level and bone marrow fibrosis in a myelofibrosis mouse model
Lara Tavernari, Matteo Bertesi, Anita Neroni, Elisa Papa, Sebastiano Rontauroli, Elisa Bianchi, Margherita Mirabile, Ruggiero Norfo, Sandra Parenti, Camilla Tombari, Chiara Carretta, Marica Malerba, Luca Fabbiani, Paola Guglielmelli, Lorena Losi, Enrico Tagliafico, Alessandro Maria Vannucchi, Rossella Manfredini, and
Blood Cancer Journal, 2025
Health-related quality of life and symptom profile of patients with BCR::ABL1-negative myeloproliferative neoplasms: Real-world evidence from the GIMEMA-PROPHECY observational study
Giovanni Caocci, Alessandro Costa, Francesca Palandri, Paola Guglielmelli, Andrea Patriarca, Alessandra Iurlo, Alessia Tieghi, Elisabetta Abruzzese, Thomas Baldi, Elena Rossi, Eloise Beggiato, Monia Marchetti, Carmen Fava, Simona Tomassetti, Elisa Rumi, Claudio Fozza, Mario Luppi, Fabrizio Pane, Sara Bigliardi, Massimo Breccia, Elena Maria Elli, Francesca Tartaglia, Olga Mulas, Paola Fazi, Marco Vignetti, Alessandro Maria Vannucchi, Fabio Efficace
Hemasphere, 2025
Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML
Francesco Mannelli, Matteo Piccini, Marco Frigeni, Giacomo Gianfaldoni, Sara Bencini, Silvia Salmoiraghi, Barbara Scappini, Benedetta Peruzzi, Roberto Caporale, Gaia Ciolli, Francesca Crupi, Laura Fasano, Elisa Quinti, Andrea Pasquini, Jessica Caroprese, Fiorenza Vanderwert, Giada Rotunno, Fabiana Pancani, Leonardo Signori, Danilo Tarantino, Chiara Maccari, Francesco Annunziato, Orietta Spinelli, Paola Guglielmelli, Alessandro Rambaldi, Alessandro M. Vannucchi
Blood Cancer Journal, 2025
Triple A Plus (AAA+) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients
Ayalew Tefferi, Giuseppe G. Loscocco, Lior Rokach, Tamar Tadmor, Priyansh Faldu, Guy Melamed, Hilel Alapi, Maymona Abdelmagid, Rania M. Abdelaziz, Muhammad Yousuf, Merry Nakhleh, Animesh Pardanani, Kebede H. Begna, Mirnal M. Patnaik, Natasha Szuber, Alessandra Carobbio, Tiziano Barbui, Kaaren K. Reichard, Rong He, Paola Guglielmelli, Naseema Gangat, Alessandro M. Vannucchi
American Journal of Hematology, 2025
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) and mature plasmacytoid dendritic cell proliferation (MPDCP): the same cell of origin from a clonal haematopoiesis of indeterminate potential (CHIP)?
Margherita Vannucchi, Maria Chiara Siciliano, Massimo Granai, Domenico Ferrara, Roberto Boccacci, Cosimo Lori, Danilo Tarantino, Leonardo Signori, Paola Guglielmelli, Lorenzo Leoncini, Stefano Lazzi
Histopathology, 2025
Clinical and Prognostic Correlates of the Reticulin-Collagen-Osteosclerosis Score in Primary Myelofibrosis
Raffaella Santi, Giacomo Coltro, Gioia Di Stefano, Alessandro Atanasio, Paolo Cicogna, Giuseppe G. Loscocco, Giulio Capecchi, Valentina Boldrini, Carlo Pescia, Paola Guglielmelli, Alessandro M. Vannucchi, Umberto Gianelli
Modern Pathology, 2025
Correction: A novel approach for highly sensitive and rapid identification of HMGA2 submicroscopic deletions in myeloproliferative neoplasms (Leukemia, (2025), 39, 8, (2042-2045), 10.1038/s41375-025-02678-4)
Niccolò Bartalucci, Danilo Tarantino, Alessio Enderti, Daniele Colazzo, Paola Guglielmelli, et al.
Leukemia, 2025
Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting dose: Analysis of AIFA registries
Massimo Breccia, Simone Celant, Francesca Palandri, Francesco Passamonti, Pier Paolo Olimpieri, Valentina Summa, Annalisa Guarcello, Giuseppe Alberto Palumbo, Fabrizio Pane, Paola Guglielmelli, Pierluigi Zinzani, Paolo Corradini, Pierluigi Russo
Annals of Hematology, 2025
A novel approach for highly sensitive and rapid identification of HMGA2 submicroscopic deletions in myeloproliferative neoplasms
Niccolò Bartalucci, Danilo Tarantino, Alessio Enderti, Daniele Colazzo, Paola Guglielmelli, Alessandro M. Vannucchi
Leukemia, 2025
CD44 Participates to Extramedullary Haematopoiesis Onset by Mediating the Interplay Between Monocytes and Haematopoietic Stem Cells in Myelofibrosis
Margherita Mirabile, Camilla Tombari, Anita Neroni, Lara Tavernari, Ruggiero Norfo, et al.
Journal of Cellular and Molecular Medicine, 2025
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design
Valerio De Stefano, Francesco Passamonti, Francesca Palandri, Francesco Ramundo, Elena Rossi, Silvia Betti, Lorenzo Fagiolo, Paola Guglielmelli, Davide Pio Abagnale, Novella Pugliese, Daniele Cattaneo, Alessandra Iurlo, Filippo Branzanti, Alessandra Dedola, Hillary Catellani, Alessia Tieghi, Marco Basso, Elisabetta Calistri, Elena Maria Elli, Elena Masselli, Erika Morsia, Giulia Benevolo, Massimo Breccia, Vincenza de Fazio, Maria Di Perna, Monia Marchetti, Marco Santoro, Agostino Tafuri, Chiara Castiglioni, Chiara Rotella, Sergio Siragusa, Alessandro Maria Vannucchi, and
Annals of Hematology, 2025
Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives
Giuseppe G. Loscocco, Paola Guglielmelli
American Journal of Hematology, 2025
Topics of Interest in Women With Myeloproliferative Neoplasms
Natasha Szuber, Paola Guglielmelli, Naseema Gangat
American Journal of Hematology, 2025
Thrombosis-Driven Disease Progression in JAK2-Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk-Based Management
Tiziano Barbui, Valerio De Stefano, Elena Rossi, Arianna Ghirardi, Alessandra Carobbio, Giuseppe Gaetano Loscocco, Annalisa Condorelli, Paola Guglielmelli
American Journal of Hematology, 2025
Multihit TP53 Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases
Saubia Fathima, Maymona Abdelmagid, Ali Alsugair, Kebede H. Begna, Aref Al‐Kali, Abhishek A. Mangaonkar, Animesh D. Pardanani, Mrinal M. Patnaik, Cinthya J. Zepeda Mendoza, Rong He, Kaaren K. Reichard, Talha Badar, James M. Foran, Jeanne Palmer, Giuseppe G. Loscocco, Paola Guglielmelli, Alessandro M. Vannucchi, Attilio Orazi, Daniel A. Arber, Devendra Hiwase, Mithun V. Shah, Naseema Gangat, Ayalew Tefferi
American Journal of Hematology, 2025
Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT
Nicola Polverelli, Juan Carlos Hernandez-Boluda, Francesco Onida, Carmelo Gurnari, Kavita Raj, Tomasz Czerw, Michelle Kenyon, Marie Robin, Katja Sockel, Annalisa Ruggeri, Isabel Sánchez-Ortega, Daniel A. Arber, Luca Arcaini, Fernando Barroso Duarte, Giorgia Battipaglia, Yves Chalandon, Fabio Ciceri, Nicholas C.P. Cross, Joanna Drozd-Sokolowska, Vaneuza Araújo Moreira Funke, Nico Gagelmann, Naseema Gangat, Jason Gotlib, Paola Guglielmelli, Claire N. Harrison, Gabriela S Hobbs, Tania Jain, Joseph D. Khoury, Jean-Jacques Kiladjian, Nicolaus Kröger, Luca Malcovati, Massimo Martino, Ruben Mesa, Attilio Orazi, Eric Padron, Francesca Palandri, Francesco Passamonti, Mrinal M. Patnaik, Naveen Pemmaraju, Deepti H. Radia, Andreas Reiter, Domenico Russo, Christof Scheid, Ayalew Tefferi, Alessandro M. Vannucchi, Daniel Howard Wiseman, Ibrahim Yakoub-Agha, Donal P McLornan
Blood, 2025
TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance
Ayalew Tefferi, Maymona Abdelmagid, Giuseppe G. Loscocco, Saubia Fathima, Kebede H. Begna, Aref Al‐Kali, James Foran, Jeanne Palmer, Talha Badar, Mrinal M. Patnaik, Kaaren K. Reichard, Rong He, Cinthya J. Zepeda Mendoza, Mithun Shah, Attilio Orazi, Daniel A. Arber, Animesh Pardanani, Alessandro M. Vannucchi, Devendra Hiwase, Naseema Gangat, Paola Guglielmelli
American Journal of Hematology, 2025
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI)
Massimo Breccia, Francesca Palandri, Maurizio Martelli, Francesco Mendicino, Alessandra Malato, Giuseppe A. Palumbo, Silvia Sibilla, Nicola Di Renzo, Elisabetta Abruzzese, Sergio Siragusa, Monica Crugnola, Carmine Selleri, Fabrizio Pane, Paolo Sportoletti, Bruno Martino, Stefana Impera, Alessandra Ricco, Maria Langella, Paolo Ditonno, Giuseppe Carli, Federico Itri, Anna Marina Liberati, Tiziana Urbano, Agostino Tafuri, Vita Polizzi, Domenico Pastore, Erika Morsia, Giulia Benevolo, Giorgia Micucci, Gabriella Farina, Massimiliano Bonifacio, Elena Maria Elli, Angelo Gardellini, Valerio De Stefano, Giovanni Caocci, Antonietta Pia Falcone, Daniele Vallisa, Marco Brociner, Mario Tiribelli, Gianni Binotto, Barbara Pocali, Francesco Cavazzini, Simona Tomassetti, Francesca Lunghi, Mauro Di Ianni, Alessandro Allegra, Barbara Anaclerio, Serena Mazzotta, Nicola Orofino, Filippo Gherlinzoni, Chiara Castiglioni, Marina Landoni, Diletta Valsecchi, Michela Magnoli, Paola Guglielmelli, Francesco Passamonti
Cancer, 2025
Essential Thrombocythemia: A Review
Ayalew Tefferi, Naseema Gangat, Giuseppe Gaetano Loscocco, Paola Guglielmelli, Natasha Szuber, Animesh Pardanani, Attilio Orazi, Tiziano Barbui, Alessandro Maria Vannucchi
JAMA, 2025
Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real-world ERNEST-2 registry
Paola Guglielmelli, Arianna Ghirardi, Alessandra Carobbio, Arianna Masciulli, Lucrezia Morrone, Barbara Mora, Elisa Rumi, Ana Triguero, Maria C. Finazzi, Helna Pettersson, Valentina Boldrini, Daniele Vanni, Alessandro Rambaldi, Francesco Passamonti, Alberto Alvarez‐Larràn, Bjorn Andreasson, Alessandro M. Vannucchi, Tiziano Barbui
Hemasphere, 2025
Mutation profiling of chronic myeloproliferative neoplasms: improving clinical-molecular prognostic models
Giuseppe G. Loscocco, Naseema Gangat, Paola Guglielmelli, Alessandro M. Vannucchi, Ayalew Tefferi
Expert Review of Molecular Diagnostics, 2025
Recommendations for best management of polycythemia vera in Italy: a Delphi consensus statement
Massimiliano Bonifacio, Massimo Breccia, Paola Guglielmelli, Francesca Palandri, Giuseppe A. Palumbo, Francesco Passamonti
Leukemia and Lymphoma, 2025
Early intervention with ruxolitinib improves spleen response in patients with myelofibrosis
Pankit Vachhani, Paola Guglielmelli, Jennifer Repp, J. E. Hamer-Maansson, Evan Braunstein, Haifa Kathrin Al-Ali
Leukemia and Lymphoma, 2025
Impact of Early-Onset or Worsening Anemia in Patients with Myelofibrosis Treated with Ruxolitinib: A post hoc Analysis of the JUMP Study
Haifa Kathrin Al-Ali, Paola Guglielmelli, Claire N. Harrison, Ruben A. Mesa, J.E. Hamer-Maansson, Evan Braunstein, Vikas Gupta
Acta Haematologica, 2025
When and how to transplant in myelofibrosis–recent trends
Naman Sharma, Giuseppe G. Loscocco, Naseema Gangat, Paola Guglielmelli, Animesh Pardanani, Alessandro M. Vannucchi, Hassan B. Alkhateeb, Ayalew Tefferi, Vincent T. Ho
Leukemia and Lymphoma, 2025
Validity and Reliability of the Self-Care in MyeloProliferative Neoplasms Inventory (SC-MPNI)
Valentina Biagioli, Alessandro Inzoli, Antonella Barone, Alessandra Iurlo, Paola Guglielmelli, Francesca Palandri, Barbara Mora, Stefana Impera, Silvia Betti, Marco Santoro, Vittorio Rosti, Giovanni Barosi
European Journal of Cancer Care, 2025
The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real-world study on AIFA monitoring registries
Massimo Breccia, Simone Celant, Francesca Palandri, Francesco Passamonti, Pier Paolo Olimpieri, Valentina Summa, Annalisa Guarcello, Giuseppe Alberto Palumbo, Fabrizio Pane, Paola Guglielmelli, Paolo Corradini, Pierluigi Russo
British Journal of Haematology, 2025
Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting
Gaia Ciolli, Matteo Piccini, Francesco Mannelli, Giacomo Gianfaldoni, Barbara Scappini, Laura Fasano, Francesca Crupi, Elisa Quinti, Andrea Pasquini, Jessica Caroprese, Giada Rotunno, Fabiana Pancani, Leonardo Signori, Chiara Maccari, Fiorenza I. Vanderwert, Paola Guglielmelli, Alessandro M. Vannucchi
Haematologica, 2025
Age-stratified analysis reveals arterial thrombosis as a predictor for gender-related second cancers in myeloproliferative neoplasms: a case-control study
Arianna Ghirardi, Alessandra Carobbio, Paola Guglielmelli, Alessandro Rambaldi, Valerio De Stefano, Alessandro M. Vannucchi, Ayalew Tefferi, Tiziano Barbui
Blood Cancer Journal, 2024
One thousand patients with essential thrombocythemia: the Florence-CRIMM experience
Giuseppe G. Loscocco, Francesca Gesullo, Giulio Capecchi, Alessandro Atanasio, Chiara Maccari, Francesco Mannelli, Alessandro M. Vannucchi, Paola Guglielmelli
Blood Cancer Journal, 2024
Neutrophil/lymphocyte ratio identifies low-risk polycythaemia vera patients for early Ropeginterferon alfa-2b therapy
Tiziano Barbui, Alessandra Carobbio, Paola Guglielmelli, Arianna Ghirardi, Francesca Fenili, Giuseppe Gaetano Loscocco, Valerio De Stefano, Francesco Ramundo, Maria Chiara Finazzi, Alessandro Rambaldi, Alessandro M. Vannucchi
British Journal of Haematology, 2024
Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in Polycythemia Vera: insights from a prospective cohort analysis
Tiziano Barbui, Alessandra Carobbio, Arianna Ghirardi, Francesca Fenili, Maria Chiara Finazzi, Marta Castelli, Alessandro M. Vannucchi, Paola Guglielmelli, Alessandro Rambaldi, Naseema Gangat, Ayalew Tefferi
Blood Cancer Journal, 2024
Hepatoid thymic carcinoma in a polycythemia vera patient treated with ropeginterferon Alfa-2b: Clinical, histopathological and molecular correlates
Giuseppe G. Loscocco, Margherita Vannucchi, Raffaella Santi, Andrea Amorosi, Stefania Scarpino, Maria Chiara Siciliano, Paola Guglielmelli, Claudio Tripodo, Arianna Di Napoli, Alessandro M. Vannucchi
Pathology Research and Practice, 2024
Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis
Ayalew Tefferi, Giovanni Barosi, Francesco Passamonti, Juan Carlos Hernandez-Boluda, Prithviraj Bose, Konstanze Döhner, Martin Ellis, Naseema Gangat, Jacqueline S. Garcia, Heinz Gisslinger, Jason Gotlib, Paola Guglielmelli, Vikas Gupta, Claire N. Harrison, Elizabeth O. Hexner, Gabriela S Hobbs, Jean-Jacques Kiladjian, Steffen Koschmieder, Nicolaus Kröger, Andrew T Kuykendall, Giuseppe Gaetano Loscocco, John O. Mascarenhas, Lucia Masarova, Ruben Mesa, Barbara Mora, Olatoyosi Odenike, Stephen T. Oh, Animesh D Pardanani, Anand A Patel, Naveen Pemmaraju, Alessandro Rambaldi, Raajit K. Rampal, Shireen Sirhan, Natasha Szuber, Moshe Talpaz, Pankit Vachhani, Alessandro M. Vannucchi, Tiziano Barbui
Blood, 2024
Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib
Giacomo Coltro, Giulio Capecchi, Margherita Maffioli, Francesco Mannelli, Barbara Mora, Alessandro Atanasio, Alessandra Iurlo, Chiara Maccari, Mirko Farina, Elena Nacca, Marianna Caramella, Leonardo Signori, Miriam Borella, Lorenza Bertù, Maria Esposito, Paola Guglielmelli, Francesco Passamonti, Alessandro Maria Vannucchi
Haematologica, 2024
Targeting exhausted cytotoxic T cells through CTLA-4 inhibition promotes elimination of neoplastic cells in human myelofibrosis xenografts
Lara Tavernari, Sebastiano Rontauroli, Ruggiero Norfo, Margherita Mirabile, Monica Maccaferri, Barbara Mora, Elena Genovese, Sandra Parenti, Chiara Carretta, Elisa Bianchi, Matteo Bertesi, Francesca Pedrazzi, Elena Tenedini, Silvia Martinelli, Maria Teresa Bochicchio, Paola Guglielmelli, Leonardo Potenza, Alessandro Lucchesi, Francesco Passamonti, Enrico Tagliafico, Mario Luppi, Alessandro Maria Vannucchi, Rossella Manfredini, and
American Journal of Hematology, 2024
Chromosome 9p trisomy increases stem cells clonogenic potential and fosters T-cell exhaustion in JAK2-mutant myeloproliferative neoplasms
Chiara Carretta, Sandra Parenti, Matteo Bertesi, Sebastiano Rontauroli, Filippo Badii, Lara Tavernari, Elena Genovese, Marica Malerba, Elisa Papa, Samantha Sperduti, Elena Enzo, Margherita Mirabile, Francesca Pedrazzi, Anita Neroni, Camilla Tombari, Barbara Mora, Margherita Maffioli, Marco Mondini, Marco Brociner, Monica Maccaferri, Elena Tenedini, Silvia Martinelli, Niccolò Bartalucci, Elisa Bianchi, Livio Casarini, Leonardo Potenza, Mario Luppi, Enrico Tagliafico, Paola Guglielmelli, Manuela Simoni, Francesco Passamonti, Ruggiero Norfo, Alessandro Maria Vannucchi, Rossella Manfredini, and
Leukemia, 2024
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia
Paola Guglielmelli, Barbara Mora, Francesca Gesullo, Francesco Mannelli, Giuseppe Gaetano Loscocco, Leonardo Signori, Chiara Pessina, Ilaria Colugnat, Raffaela Aquila, Manjola Balliu, Chiara Maccari, Simone Romagnoli, Chiara Paoli, Elena Nacca, Lorenzo Fagiolo, Margherita Maffioli, Tiziano Barbui, Francesco Passamonti, Alessandro M. Vannucchi
American Journal of Hematology, 2024
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial
Bianca Rocca, Alberto Tosetto, Giovanna Petrucci, Elena Rossi, Silvia Betti, Denise Soldati, Alessandra Iurlo, Daniele Cattaneo, Cristina Bucelli, Alfredo Dragani, Mauro Di Ianni, Paola Ranalli, Francesca Palandri, Nicola Vianelli, Eloise Beggiato, Giuseppe Lanzarone, Marco Ruggeri, Giuseppe Carli, Elena Maria Elli, Rossella Renso, Maria Luigia Randi, Irene Bertozzi, Giuseppe Gaetano Loscocco, Alessandra Ricco, Giorgina Specchia, Alessandro M. Vannucchi, Francesco Rodeghiero, Valerio De Stefano, Carlo Patrono, and
American Journal of Hematology, 2024
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options
Jean-Jacques Kiladjian, Francisca Ferrer Marin, Haifa Kathrin Al-Ali, Alberto Alvarez-Larrán, Eloise Beggiato, Maria Bieniaszewska, Massimo Breccia, Veronika Buxhofer-Ausch, Olga Cerna, Ana-Manuela Crisan, Catalin Doru Danaila, Valerio De Stefano, Konstanze Döhner, Victoria Empson, Joanna Gora-Tybor, Martin Griesshammer, Sebastian Grosicki, Paola Guglielmelli, Valentin García-Gutierrez, Florian H. Heidel, Arpád Illés, Ciprian Tomuleasa, Chloe James, Steffen Koschmieder, Maria-Theresa Krauth, Kurt Krejcy, Mihaela-Cornelia Lazaroiu, Jiri Mayer, Zsolt György Nagy, Franck-Emmanuel Nicolini, Francesca Palandri, Vassiliki Pappa, Andreas Johannes Reiter, Tomasz Sacha, Stefanie Schlager, Stefan Schmidt, Evangelos Terpos, Martin Unger, Albert Wölfler, Blanca Xicoy Cirici, Christoph Klade
Annals of Hematology, 2024
CALR mutation burden in essential thrombocythemia and disease outcome
Paola Guglielmelli, Natasha Szuber, Naseema Gangat, Giulio Capecchi, Chiara Maccari, Michaël Harnois, Omer Karrar, Maymona Abdelmagid, Manjola Balliu, Elena Nacca, Alessandro Atanasio, Ilaria Sestini, Audrey Desilets, Giuseppe Gaetano Loscocco, Giada Rotunno, Lambert Busque, Ayalew Tefferi, Alessandro Maria Vannucchi
Blood, 2024
Functional relevance of circRNA aberrant expression in pediatric acute leukemia with KMT2A::AFF1 fusion
Caterina Tretti Parenzan, Anna Dal Molin, Giorgia Longo, Enrico Gaffo, Alessia Buratin, Alice Cani, Elena Boldrin, Valentina Serafin, Paola Guglielmelli, Alessandro M. Vannucchi, Giovanni Cazzaniga, Andrea Biondi, Franco Locatelli, Lueder H. Meyer, Barbara Buldini, Geertruij te Kronnie, Silvia Bresolin, Stefania Bortoluzzi
Blood Advances, 2024
Inherited polygenic effects on common hematological traits influence clonal selection on JAK2 V617F and the development of myeloproliferative neoplasms
Jing Guo, Klaudia Walter, Pedro M. Quiros, Muxin Gu, E. Joanna Baxter, John Danesh, Emanuele Di Angelantonio, David Roberts, Paola Guglielmelli, Claire N. Harrison, Anna L. Godfrey, Anthony R. Green, George S. Vassiliou, Dragana Vuckovic, Jyoti Nangalia, Nicole Soranzo
Nature Genetics, 2024
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes
Tiziano Barbui, Alessandra Carobbio, Valerio De Stefano, Alberto Alvarez-Larran, Arianna Ghirardi, Greta Carioli, Francesca Fenili, Elena Rossi, Fabio Ciceri, Massimiliano Bonifacio, Alessandra Iurlo, Francesca Palandri, Giulia Benevolo, Fabrizio Pane, Alessandra Ricco, Giuseppe Carli, Marianna Caramella, Davide Rapezzi, Caterina Musolino, Sergio Siragusa, Elisa Rumi, Andrea Patriarca, Nicola Cascavilla, Barbara Mora, Emma Cacciola, Laura Calabresi, Giuseppe Gaetano Loscocco, Paola Guglielmelli, Francesca Gesullo, Silvia Betti, Francesco Ramundo, Francesca Lunghi, Luigi Scaffidi, Cristina Bucelli, Daniele Cattaneo, Nicola Vianelli, Marta Bellini, Maria Chiara Finazzi, Gianni Tognoni, Alessandro Rambaldi, Alessandro Maria Vannucchi
Annals of Hematology, 2024
A safety evaluation of ruxolitinib for the treatment of polycythemia vera
Valentina Boldrini, Alessandro M. Vannucchi, Paola Guglielmelli
Expert Opinion on Drug Safety, 2024
δβ-Thalassemia and α-Triplication: Is Genetic Retesting Worthwhile in Case of Non-Coherent Phenotype?
Cristina Giubbilei, Simona D’Angelo, Ilaria Fotzi, Massimo Mogni, Paola Guglielmelli, Alessandro Maria Vannucchi, Valentina Carrai
Hemoglobin, 2024
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis
Giuseppe G. Loscocco, Giada Rotunno, Francesco Mannelli, Giacomo Coltro, Francesca Gesullo, Fabiana Pancani, Leonardo Signori, Chiara Maccari, Maria Esposito, Chiara Paoli, Alessandro M. Vannucchi, Paola Guglielmelli
American Journal of Hematology, 2024
Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia
Francesco Mannelli, Matteo Piccini, Sara Bencini, Giacomo Gianfaldoni, Benedetta Peruzzi, Roberto Caporale, Barbara Scappini, Laura Fasano, Elisa Quinti, Gaia Ciolli, Andrea Pasquini, Francesca Crupi, Sofia Pilerci, Fabiana Pancani, Leonardo Signori, Danilo Tarantino, Chiara Maccari, Vivian Paradiso, Francesco Annunziato, Paola Guglielmelli, Alessandro M. Vannucchi
Haematologica, 2024
A globally applicable “triple A” risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count
Ayalew Tefferi, Giuseppe G. Loscocco, Faiqa Farrukh, Natasha Szuber, Francesco Mannelli, Animesh Pardanani, Curtis A. Hanson, Rhett P. Ketterling, Valerio De Stefano, Alessandra Carobbio, Tiziano Barbui, Paola Guglielmelli, Naseema Gangat, Alessandro M. Vannucchi
American Journal of Hematology, 2023
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis
Paola Guglielmelli, Chiara Maccari, Benedetta Sordi, Manjola Balliu, Alessandro Atanasio, Carmela Mannarelli, Giulio Capecchi, Ilaria Sestini, Giacomo Coltro, Giuseppe Gaetano Loscocco, Giada Rotunno, Eva Angori, Filippo C. Borri, Ayalew Tefferi, Alessandro M. Vannucchi
Blood Cancer Journal, 2023
Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms
Laura Calabresi, Chiara Carretta, Simone Romagnoli, Giada Rotunno, Sandra Parenti, Matteo Bertesi, Niccolò Bartalucci, Sebastiano Rontauroli, Chiara Chiereghin, Sara Castellano, Giulia Gentili, Chiara Maccari, Fiorenza Vanderwert, Francesco Mannelli, Matteo Della Porta, Rossella Manfredini, Alessandro Maria Vannucchi, Paola Guglielmelli
American Journal of Hematology, 2023
Acute Myocardial Infarction and Chronic Myeloproliferative Neoplasms: Friend and Enemy, Depending on Circumstances
Alessandro Maria Vannucchi, Paola Guglielmelli
Jacc Cardiooncology, 2023
Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy
A. Atanasio, A. Vanni, L. Maggi, S. Pilerci, A. Mazzoni, M. Capone, F. Crupi, P. Cicogna, V. Boldrini, S. Tekle, M.G. Colao, M. Borella, C. Paoli, G.M. Rossolini, A.M. Vannucchi, F. Annunziato, P. Guglielmelli
Leukemia Research, 2023
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera
Tiziano Barbui, Alessandro Maria Vannucchi, Valerio De Stefano, Alessandra Carobbio, Arianna Ghirardi, Greta Carioli, Arianna Masciulli, Elena Rossi, Fabio Ciceri, Massimiliano Bonifacio, Alessandra Iurlo, Francesca Palandri, Giulia Benevolo, Fabrizio Pane, Alessandra Ricco, Giuseppe Carli, Marianna Caramella, Davide Rapezzi, Caterina Musolino, Sergio Siragusa, Elisa Rumi, Andrea Patriarca, Nicola Cascavilla, Barbara Mora, Emma Cacciola, Carmela Mannarelli, Giuseppe Gaetano Loscocco, Paola Guglielmelli, Francesca Gesullo, Silvia Betti, Francesca Lunghi, Luigi Scaffidi, Cristina Bucelli, Nicola Vianelli, Marta Bellini, Maria Chiara Finazzi, Gianni Tognoni, Alessandro Rambaldi
Nejm Evidence, 2023
Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP Study
Francesca Palandri, Haifa Kathrin Al-Ali, Paola Guglielmelli, Mike W. Zuurman, Rajendra Sarkar, Vikas Gupta
Cancers, 2023
Inhibition of CXCR1/2 reduces the emperipolesis between neutrophils and megakaryocytes in the Gata1low model of myelofibrosis
Francesca Arciprete, Paola Verachi, Fabrizio Martelli, Mauro Valeri, Manjola Balliu, Paola Guglielmelli, Alessandro Maria Vannucchi, Anna Rita Migliaccio, Maria Zingariello
Experimental Hematology, 2023
Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model
Elisa Bianchi, Sebastiano Rontauroli, Lara Tavernari, Margherita Mirabile, Francesca Pedrazzi, Elena Genovese, Stefano Sartini, Massimiliano Dall’Ora, Giulia Grisendi, Luca Fabbiani, Monica Maccaferri, Chiara Carretta, Sandra Parenti, Sebastian Fantini, Niccolò Bartalucci, Laura Calabresi, Manjola Balliu, Paola Guglielmelli, Leonardo Potenza, Enrico Tagliafico, Lorena Losi, Massimo Dominici, Mario Luppi, Alessandro Maria Vannucchi, Rossella Manfredini
Leukemia, 2023
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project
Giacomo Coltro, Emanuela Sant'Antonio, Giuseppe A. Palumbo, Francesco Mannelli, Valerio De Stefano, Marco Ruggeri, Elena M. Elli, Roberta Zanotti, Oscar Borsani, Irene Bertozzi, Andrea Duminuco, Silvia Betti, Giuseppe Carli, Fabrizio Cavalca, Ilaria Tanasi, Elisa Rumi, Maria L. Randi, Bruno Garibaldi, Giuseppe G. Loscocco, Paola Guglielmelli, Alessandro M. Vannucchi
Cancer Medicine, 2023
Diagnostic and therapeutic challenges in mast cell sarcoma
Francesco Mannelli, Francesca Gesullo, Carmela Mannarelli, Fiorenza Vanderwert, Stefano Lazzi, Francesco Mungai, Valentina Berti, Raffaella Santi, Paola Guglielmelli, Alessandro M. Vannucchi
American Journal of Hematology, 2023
Management of polycythemia vera: A survey of treatment patterns in Italy
Giuseppe Alberto Palumbo, Massimo Breccia, Claudia Baratè, Massimiliano Bonifacio, Elena Maria Elli, Alessandra Iurlo, Novella Pugliese, Elena Rossi, Paola Guglielmelli, Francesca Palandri
European Journal of Haematology, 2023
Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis
Benedetta Sordi, Fiorenza Vanderwert, Francesca Crupi, Francesca Gesullo, Roberta Zanotti, Patrizia Bonadonna, Lara Crosera, Chiara Elena, Nicolas Fiorelli, Jacqueline Ferrari, Federica Grifoni, Mariarita Sciumè, Roberta Parente, Massimo Triggiani, Boaz Palterer, Valentina Mecheri, Fabio Almerigogna, Raffaella Santi, Lisa Di Medio, Maria Luisa Brandi, Maria Loredana Iorno, Isabella Ciardetti, Sara Bencini, Francesco Annunziato, Carmela Mannarelli, Lisa Pieri, Paola Guglielmelli, Francesco Mannelli, Alessandro M. Vannucchi
Journal of Allergy and Clinical Immunology, 2023
ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms
Francesco Mannelli, Paola Guglielmelli, Paola Fazi, Enrico Crea, Alfonso Piciocchi, Marco Vignetti, Sergio Amadori, Fabrizio Pane, Adriano Venditti, Alessandro M Vannucchi
Future Oncology, 2023
The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis
Francesco Mannelli, Francesca Crupi, Roberta Zanotti, Livio Pagano, Davide Rapezzi, Ilaria Tanasi, Marianna Criscuolo, Massimiliano Bonifacio, Alberto Fresa, Paola Guglielmelli, Alessandro M. Vannucchi
Therapeutic Advances in Hematology, 2023
Molecular prognostication in Ph-negative MPNs in 2022
Alessandro Maria Vannucchi, Paola Guglielmelli
Hematology United States, 2022
Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis
Giuseppe G. Loscocco, Raffaella Santi, Valentina Carrai, Giacomo Coltro, Francesco Mannelli, Paola Guglielmelli, Alessandro M. Vannucchi
International Journal of Laboratory Hematology, 2022
Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19
Tiziano Barbui, Alessandra Carobbio, Arianna Ghirardi, Alessandra Iurlo, Marta Anna Sobas, Elena Maria Elli, Elisa Rumi, Valerio De Stefano, Francesca Lunghi, Monia Marchetti, Rosa Daffini, Mercedes Gasior Kabat, Beatriz Cuevas, Maria Laura Fox, Marcio Miguel Andrade‐Campos, Francesca Palandri, Paola Guglielmelli, Giulia Benevolo, Claire Harrison, Maria‐Angeles Foncillas, Massimiliano Bonifacio, Alberto Alvarez‐Larran, Jean‐Jacques Kiladjian, Estefanía Bolaños Calderón, Andrea Patriarca, Keina Quiroz Cervantes, Martin Griesshammer, Valentin Garcia‐Gutierrez, Alberto Marin Sanchez, Elena Magro Mazo, Giuseppe Carli, Juan Carlos Hernandez‐Boluda, Santiago Osorio, Gonzalo Carreno‐Tarragona, Miguel Sagues Serrano, Rajko Kusec, Begona Navas Elorza, Anna Angona, Blanca Xicoy Cirici, Emma Lopez Abadia, Steffen Koschmieder, Daniele Cattaneo, Cristina Bucelli, Edyta Cichocka, Anna Kulikowska de Nałęcz, Fabrizio Cavalca, Oscar Borsani, Silvia Betti, Marta Bellini, Natalia Curto‐Garcia, Alessandro Rambaldi, Alessandro Maria Vannucchi
American Journal of Hematology, 2022
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
Tiziano Barbui, Arianna Ghirardi, Alessandra Carobbio, Arianna Masciulli, Greta Carioli, Alessandro Rambaldi, Maria Chiara Finazzi, Marta Bellini, Elisa Rumi, Daniele Vanni, Oscar Borsani, Francesco Passamonti, Barbara Mora, Marco Brociner, Paola Guglielmelli, Chiara Paoli, Alberto Alvarez-Larran, Ana Triguero, Marta Garrote, Helna Pettersson, Björn Andréasson, Giovanni Barosi, Alessandro Maria Vannucchi
Blood Cancer Journal, 2022
Breakthrough infections in MPN-COVID vaccinated patients
Tiziano Barbui, Alessandra Carobbio, Arianna Ghirardi, Alessandra Iurlo, Valerio De Stefano, Marta Anna Sobas, Elisa Rumi, Elena Maria Elli, Francesca Lunghi, Mercedes Gasior Kabat, Beatriz Cuevas, Paola Guglielmelli, Massimiliano Bonifacio, Monia Marchetti, Alberto Alvarez-Larran, Laura Fox, Marta Bellini, Rosa Daffini, Giulia Benevolo, Gonzalo Carreno-Tarragona, Andrea Patriarca, Haifa Kathrin Al-Ali, Maria Marcio Miguel Andrade-Campos, Francesca Palandri, Claire Harrison, Maria Angeles Foncillas, Santiago Osorio, Steffen Koschmieder, Elena Magro Mazo, Jean-Jacques Kiladjian, Estefanía Bolaños Calderón, Florian H. Heidel, Keina Quiroz Cervantes, Martin Griesshammer, Valentin Garcia-Gutierrez, Alberto Marin Sanchez, Juan Carlos Hernandez-Boluda, Emma Lopez Abadia, Giuseppe Carli, Miguel Sagues Serrano, Rajko Kusec, Blanca Xicoy Cirici, Margarita Guenova, Begona Navas Elorza, Anna Angona, Edyta Cichocka, Anna Kulikowska de Nałęcz, Daniele Cattaneo, Cristina Bucelli, Silvia Betti, Oscar Borsani, Fabrizio Cavalca, Sara Carbonell, Natalia Curto-Garcia, Lina Benajiba, Alessandro Rambaldi, Alessandro Maria Vannucchi
Blood Cancer Journal, 2022
Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine
M. Breccia, A. Piciocchi, M. Messina, S. Soddu, V. De Stefano, M. Bellini, A. Iurlo, B. Martino, S. Siragusa, F. Albano, B. Mora, P. Fazi, M. Vignetti, P. Guglielmelli, F. Palandri
Leukemia, 2022
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients
Barbara Mora, Paola Guglielmelli, Andrew Kuykendall, Elisa Rumi, Margherita Maffioli, Francesca Palandri, Valerio De Stefano, Marianna Caramella, Silvia Salmoiraghi, Jean-Jacques Kiladjian, Jason Gotlib, Alessandra Iurlo, Francisco Cervantes, Marco Ruggeri, Richard T. Silver, Francesco Albano, Giulia Benevolo, David M. Ross, Matteo G. Della Porta, Timothy Devos, Giada Rotunno, Rami S. Komrokji, Ilaria C. Casetti, Michele Merli, Marco Brociner, Domenica Caramazza, Giuseppe Auteri, Tiziano Barbui, Daniele Cattaneo, Lorenza Bertù, Luca Arcaini, Alessandro M. Vannucchi, Francesco Passamonti
Leukemia, 2022
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates
Giuseppe G. Loscocco, Paola Guglielmelli, Francesco Mannelli, Barbara Mora, Carmela Mannarelli, Giada Rotunno, Fabiana Pancani, Chiara Maccari, Niccolò Bartalucci, Simone Romagnoli, Giacomo Coltro, Francesco Passamonti, Alessandro M. Vannucchi
American Journal of Hematology, 2022
Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis
Giacomo Coltro, Francesco Mannelli, Giuseppe Gaetano Loscocco, Carmela Mannarelli, Giada Rotunno, Chiara Maccari, Fabiana Pancani, Alessandro Atanasio, Alessandro Maria Vannucchi, Paola Guglielmelli
Blood Cancer Journal, 2022
Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance
Massimo Breccia, Francesca Palandri, Paola Guglielmelli, Giuseppe Alberto Palumbo, Alessandra Malato, Francesco Mendicino, Alessandra Ricco, Emanuela Sant’Antonio, Mario Tiribelli, Alessandra Iurlo
Current Oncology, 2022
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study
Francesco Passamonti, Francesca Palandri, Guray Saydam, Jeannie Callum, Timothy Devos, Paola Guglielmelli, Alessandro M Vannucchi, Evren Zor, Mike Zuurman, Geralyn Gilotti, Yifan Zhang, Martin Griesshammer
Lancet Haematology, 2022
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis
Francesco Mannelli, Sara Bencini, Giacomo Coltro, Giuseppe G. Loscocco, Benedetta Peruzzi, Giada Rotunno, Chiara Maccari, Francesca Gesullo, Miriam Borella, Chiara Paoli, Roberto Caporale, Carmela Mannarelli, Francesco Annunziato, Paola Guglielmelli, Alessandro M. Vannucchi
American Journal of Hematology, 2022
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera
Paola Guglielmelli, Giacomo Coltro, Francesco Mannelli, Giada Rotunno, Giuseppe G. Loscocco, Carmela Mannarelli, Chiara Maccari, Chiara Paoli, Simone Romagnoli, Niccolò Bartalucci, Alessandro M. Vannucchi
Blood Advances, 2022
JAK inhibitors and COVID-19
Gabriel Levy, Paola Guglielmelli, Peter Langmuir, Stefan N Constantinescu
Journal for Immunotherapy of Cancer, 2022
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations
Monia Marchetti, Alessandro Maria Vannucchi, Martin Griesshammer, Claire Harrison, Steffen Koschmieder, Heinz Gisslinger, Alberto Álvarez-Larrán, Valerio De Stefano, Paola Guglielmelli, Francesca Palandri, Francesco Passamonti, Giovanni Barosi, Richard T Silver, Rüdiger Hehlmann, Jean-Jacques Kiladjian, Tiziano Barbui
Lancet Haematology, 2022
Second versus first wave of COVID-19 in patients with MPN
Tiziano Barbui, Alessandra Iurlo, Arianna Masciulli, Alessandra Carobbio, Arianna Ghirardi, Greta Carioli, Marta Anna Sobas, Elena Maria Elli, Elisa Rumi, Valerio De Stefano, Francesca Lunghi, Monia Marchetti, Rosa Daffini, Mercedes Gasior Kabat, Beatriz Cuevas, Maria Laura Fox, Marcio Miguel Andrade-Campos, Francesca Palandri, Paola Guglielmelli, Giulia Benevolo, Claire Harrison, Maria Angeles Foncillas, Massimiliano Bonifacio, Alberto Alvarez-Larran, Jean-Jacques Kiladjian, Estefanía Bolaños Calderón, Andrea Patriarca, Keina Quiroz Cervantes, Martin Griessammer, Valentin Garcia-Gutierrez, Alberto Marin Sanchez, Elena Magro Mazo, Marco Ruggeri, Juan Carlos Hernandez-Boluda, Santiago Osorio, Gonzalo Carreno-Tarragona, Miguel Sagues Serrano, Rajko Kusec, Begona Navas Elorza, Anna Angona, Blanca Xicoy Cirici, Emma Lopez Abadia, Steffen Koschmieder, Daniele Cattaneo, Cristina Bucelli, Edyta Cichocka, Anna Masternak Kulikowska de Nałęcz, Fabrizio Cavalca, Oscar Borsani, Silvia Betti, Lina Benajiba, Marta Bellini, Natalia Curto-Garcia, Alessandro Rambaldi, Alessandro Maria Vannucchi
Leukemia, 2022
Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia
Faiqa Farrukh, Paola Guglielmelli, Giuseppe G. Loscocco, Animesh Pardanani, Curtis A. Hanson, Valerio De Stefano, Tiziano Barbui, Naseema Gangat, Alessandro M. Vannucchi, Ayalew Tefferi
American Journal of Hematology, 2022
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera
Alessandra Carobbio, Alessandro Maria Vannucchi, Valerio De Stefano, Arianna Masciulli, Paola Guglielmelli, Giuseppe Gaetano Loscocco, Francesco Ramundo, Elena Rossi, Yogendra Kanthi, Ayalew Tefferi, Tiziano Barbui
Blood Cancer Journal, 2022
Portosystemic shunt is an effective treatment for complications of portal hypertension in hepatic myeloid metaplasia and improves nutritional status
Silvia Aspite, Filippo Schepis, Davide Roccarina, Stefano Gitto, Michele Citone, Chiara Di Bonaventura, Marcello Bianchini, Umberto Arena, Alessandro M. Vannucchi, Paola Guglielmelli, Francesca Campani, Fabrizio Fanelli, Fabio Marra, Francesco Vizzutti
Liver International, 2022
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study
Paola Guglielmelli, Arianna Ghirardi, Alessandra Carobbio, Arianna Masciulli, Chiara Maccari, Barbara Mora, Elisa Rumi, Ana Triguero, Maria Chiara Finazzi, Helna Pettersson, Chiara Paoli, Francesco Mannelli, Daniele Vanni, Alessandro Rambaldi, Francesco Passamonti, Alberto Alvarez-Larràn, Bjorn Andreasson, Alessandro M. Vannucchi, Tiziano Barbui
Blood Advances, 2022
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI)
Paola Guglielmelli, Francesca Palandri, Carmine Selleri, Daniela Cilloni, Francesco Mendicino, Patrizio Mazza, Domenico Pastore, Giuseppe A. Palumbo, Marco Santoro, Vincenzo Pavone, Stefana Impera, Mara Morelli, Paola Coco, Diletta Valsecchi, Francesco Passamonti, Massimo Breccia, and
Leukemia and Lymphoma, 2022
Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 109/L to <100 × 109/L) at baseline: the final analysis of EXPAND
Paola Guglielmelli, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Minghui Duan, Haitao Meng, Ling Pan, Guangsheng He, Srdan Verstovsek, Françoise Boyer, Fiorenza Barraco, Dietger Niederwieser, Ester Pungolino, Anna Marina Liberati, Claire Harrison, Pantelia Roussou, Monika Wroclawska, Divyadeep Karumanchi, Karen Sinclair, Peter A.W. te Boekhorst, Heinz Gisslinger
Therapeutic Advances in Hematology, 2022
The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis
Elena Genovese, Margherita Mirabile, Sebastiano Rontauroli, Stefano Sartini, Sebastian Fantini, Lara Tavernari, Monica Maccaferri, Paola Guglielmelli, Elisa Bianchi, Sandra Parenti, Chiara Carretta, Selene Mallia, Sara Castellano, Corrado Colasante, Manjola Balliu, Niccolò Bartalucci, Raffaele Palmieri, Tiziana Ottone, Barbara Mora, Leonardo Potenza, Francesco Passamonti, Maria Teresa Voso, Mario Luppi, Alessandro Maria Vannucchi, Enrico Tagliafico, Rossella Manfredini, and
Antioxidants, 2022
BRAFV600E mutation in the wrong place: a case of concomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma
Giuseppe G. Loscocco, Giada Rotunno, Lara Mannelli, Francesco Mannelli, Federica Vergoni, Paola Guglielmelli, Alessandro M. Vannucchi
Tumori, 2021
Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases
Naseema Gangat, Paola Guglielmelli, Silvia Betti, Faiqa Farrukh, Alessandra Carobbio, Tiziano Barbui, Alessandro M. Vannucchi, Valerio De Stefano, Ayalew Tefferi
American Journal of Hematology, 2021
Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2
Simone Romagnoli, Niccolò Bartalucci, Francesca Gesullo, Manjola Balliu, Stefania Bonifacio, Anair Graciela Lema Fernandez, Francesco Mannelli, Davide Bolognini, Elisabetta Pelo, Cristina Mecucci, Paola Guglielmelli, Alessandro Maria Vannucchi
Biomarker Research, 2021
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis
Paola Guglielmelli, Giuseppe G. Loscocco, Carmela Mannarelli, Elena Rossi, Francesco Mannelli, Francesco Ramundo, Giacomo Coltro, Silvia Betti, Chiara Maccari, Sara Ceglie, Patrizia Chiusolo, Chiara Paoli, Tiziano Barbui, Ayalew Tefferi, Valerio De Stefano, Alessandro M. Vannucchi
Blood Cancer Journal, 2021
Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib
Paola Guglielmelli, Alessio Mazzoni, Laura Maggi, Seble Tekle Kiros, Lorenzo Zammarchi, Sofia Pilerci, Arianna Rocca, Michele Spinicci, Miriam Borella, Alessandro Bartoloni, Gian Maria Rossolini, Francesco Annunziato, Alessandro M. Vannucchi
American Journal of Hematology, 2021
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients
Giuseppe G. Loscocco, Paola Guglielmelli, Naseema Gangat, Elena Rossi, Carmela Mannarelli, Silvia Betti, Chiara Maccari, Francesco Ramundo, Yamna Jadoon, Francesca Gesullo, Sara Ceglie, Chiara Paoli, Animesh Pardanani, Valerio De Stefano, Ayalew Tefferi, Alessandro M. Vannucchi
American Journal of Hematology, 2021
Pregnancy in patients with myelofibrosis: Mayo–Florence series of 24 pregnancies in 16 women
Naseema Gangat, Paola Guglielmelli, Aref Al‐Kali, Alexandra P. Wolanskyj‐Spinner, John Camoriano, Mrinal M. Patnaik, Animesh Pardanani, Curtis A. Hanson, Alessandro M. Vannucchi, Ayalew Tefferi
British Journal of Haematology, 2021
AMELIORATE: Early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance - MYNERVA-GIMEMA AML1919 trial
Francesco Mannelli, Giacomo Gianfaldoni, Paola Guglielmelli, Francesco Buccisano, Roberto Caporale, Marco Chiarini, Giuseppe Rossi, Adriano Venditti, Paola Fazi, Enrico Crea, Alfonso Piciocchi, Maria Teresa Voso, Marco Vignetti, Sergio Amadori, Alessandro Maria Vannucchi
Future Oncology, 2021
Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study
Francesco Passamonti, Vikas Gupta, Bruno Martino, Lynda Foltz, Andrey Zaritskey, Haifa Kathrin Al‐Ali, Renato Tavares, Margherita Maffioli, Pia Raanani, Pilar Giraldo, Martin Griesshammer, Paola Guglielmelli, Catherine Bouard, Carole Paley, Ranjan Tiwari, Alessandro M. Vannucchi
Hematological Oncology, 2021
Increased plasma levels of lncrnas linc01268, gas5 and malat1 correlate with negative prognostic factors in myelofibrosis
Sebastian Fantini, Sebastiano Rontauroli, Stefano Sartini, Margherita Mirabile, Elisa Bianchi, Filippo Badii, Monica Maccaferri, Paola Guglielmelli, Tiziana Ottone, Raffaele Palmieri, Elena Genovese, Chiara Carretta, Sandra Parenti, Selene Mallia, Lara Tavernari, Costanza Salvadori, Francesca Gesullo, Chiara Maccari, Michela Zizza, Alexis Grande, Silvia Salmoiraghi, Barbara Mora, Leonardo Potenza, Vittorio Rosti, Francesco Passamonti, Alessandro Rambaldi, Maria Teresa Voso, Cristina Mecucci, Enrico Tagliafico, Mario Luppi, Alessandro Maria Vannucchi, Rossella Manfredini
Cancers, 2021
Integration of molecular information in risk assessment of patients with myeloproliferative neoplasms
Giuseppe G. Loscocco, Giacomo Coltro, Paola Guglielmelli, Alessandro M. Vannucchi
Cells, 2021
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2 P95-mutated neoplasms
Gabriele Todisco, Maria Creignou, Anna Gallì, Paola Guglielmelli, Elisa Rumi, Marco Roncador, Ettore Rizzo, Yasuhito Nannya, Daniela Pietra, Chiara Elena, Elisa Bono, Elisabetta Molteni, Vittorio Rosti, Silvia Catricalá, Martina Sarchi, Marios Dimitriou, Johanna Ungerstedt, Alessandro Maria Vannucchi, Eva Hellström-Lindberg, Seishi Ogawa, Mario Cazzola, Luca Malcovati
Leukemia, 2021
Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases
Naseema Gangat, Paola Guglielmelli, Natasha Szuber, Kebede H. Begna, Mrinal M. Patnaik, Mark R. Litzow, Aref Al‐Kali, James M. Foran, Jeanne M. Palmer, Hassan Alkhateeb, Michelle A. Elliott, Curtis A. Hanson, Animesh Pardanani, Francesco Mannelli, Alessandro M. Vannucchi, Ayalew Tefferi
American Journal of Hematology, 2021
Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis
Giuseppe G. Loscocco, Elisabetta Antonioli, Ilaria Romano, Federica Vergoni, Giada Rotunno, Francesco Mannelli, Paola Guglielmelli, Alessandro M. Vannucchi
American Journal of Hematology, 2021
Long-term follow-up of recovered MPN patients with COVID-19
Tiziano Barbui, Alessandra Iurlo, Arianna Masciulli, Alessandra Carobbio, Arianna Ghirardi, Giuseppe Rossi, Claire Harrison, Alberto Alvarez-Larran, Elena Maria Elli, Jean-Jaques Kiladjian, Mercedes Gasior Kabat, Alberto Marin Sanchez, Francesca Palandri, Marcio Miguel Andrade-Campos, Alessandro Maria Vannucchi, Gonzalo Carreno-Tarragona, Petros Papadopoulos, Keina Quiroz Cervantes, Maria Angeles Foncillas, Maria Laura Fox, Miguel Sagues Serrano, Elisa Rumi, Santiago Osorio, Giulia Benevolo, Andrea Patriarca, Begona Navas Elorza, Valentin Garcia-Gutierrez, Elena Magro Mazo, Francesca Lunghi, Massimiliano Bonifacio, Valerio De Stefano, Juan Carlos Hernandez-Boluda, Emma Lopez Abadia, Anna Angona, Blanca Xicoy Cirici, Marco Ruggeri, Steffen Koschmieder, Marta Anna Sobas, Beatriz Cuevas, Daniele Cattaneo, Rosa Daffini, Marta Bellini, Natalia Curto-Garcia, Marta Garrote, Fabrizio Cavalca, Lina Benajiba, Beatriz Bellosillo, Paola Guglielmelli, Oscar Borsani, Silvia Betti, Silvia Salmoiraghi, Alessandro Rambaldi
Blood Cancer Journal, 2021
Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs
Manjola Balliu, Laura Calabresi, Niccolò Bartalucci, Simone Romagnoli, Laura Maggi, Rossella Manfredini, Matteo Lulli, Paola Guglielmelli, Alessandro Maria Vannucchi
Blood Advances, 2021
Mutations and thrombosis in essential thrombocythemia
Paola Guglielmelli, Naseema Gangat, Giacomo Coltro, Terra L. Lasho, Giuseppe Gaetano Loscocco, Christy M. Finke, Erika Morsia, Benedetta Sordi, Natasha Szuber, Curtis A. Hanson, Animesh Pardanani, Alessandro M. Vannucchi, Ayalew Tefferi
Blood Cancer Journal, 2021
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study
Alessandro M. Vannucchi, Benedetta Sordi, Alessandro Morettini, Carlo Nozzoli, Loredana Poggesi, Filippo Pieralli, Alessandro Bartoloni, Alessandro Atanasio, Filippo Miselli, Chiara Paoli, Giuseppe G. Loscocco, Andrea Fanelli, Ombretta Para, Andrea Berni, Irene Tassinari, Lorenzo Zammarchi, Laura Maggi, Alessio Mazzoni, Valentina Scotti, Giorgia Falchetti, Danilo Malandrino, Fabio Luise, Giovanni Millotti, Sara Bencini, Manuela Capone, Marie Pierre Piccinni, Francesco Annunziato, Paola Guglielmelli, Francesco Mannelli, Giacomo Coltro, Duccio Fantoni, Miriam Borella, Enrica Ravenda, Benedetta Peruzzi, Roberto Caporale, Lorenzo Cosmi, Francesco Liotta, Letizia Lombardelli, Federica Logiodice, Anna Vanni, Lorenzo Salvati, Chiara Lazzeri, Manuela Bonizzoli, Adriano Peris, Giovanni Cianchi, Alberto Bosi, Michela Pucatti, Paolo Fontanari, Silvia Benemei, Marco Matucci Cerinic, Lucia Turco, and
Leukemia, 2021
Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis
Sebastiano Rontauroli, Sara Castellano, Paola Guglielmelli, Roberta Zini, Elisa Bianchi, Elena Genovese, Chiara Carretta, Sandra Parenti, Sebastian Fantini, Selene Mallia, Lara Tavernari, Stefano Sartini, Margherita Mirabile, Carmela Mannarelli, Francesca Gesullo, Annalisa Pacilli, Daniela Pietra, Elisa Rumi, Silvia Salmoiraghi, Barbara Mora, Laura Villani, Andrea Grilli, Vittorio Rosti, Giovanni Barosi, Francesco Passamonti, Alessandro Rambaldi, Luca Malcovati, Mario Cazzola, Silvio Bicciato, Enrico Tagliafico, Alessandro M. Vannucchi, Rossella Manfredini
Blood Advances, 2021
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial
Tiziano Barbui, Alessandro Maria Vannucchi, Valerio De Stefano, Arianna Masciulli, Alessandra Carobbio, Alberto Ferrari, Arianna Ghirardi, Elena Rossi, Fabio Ciceri, Massimiliano Bonifacio, Alessandra Iurlo, Francesca Palandri, Giulia Benevolo, Fabrizio Pane, Alessandra Ricco, Giuseppe Carli, Marianna Caramella, Davide Rapezzi, Caterina Musolino, Sergio Siragusa, Elisa Rumi, Andrea Patriarca, Nicola Cascavilla, Barbara Mora, Emma Cacciola, Carmela Mannarelli, Giuseppe Gaetano Loscocco, Paola Guglielmelli, Silvia Betti, Francesca Lunghi, Luigi Scaffidi, Cristina Bucelli, Nicola Vianelli, Marta Bellini, Maria Chiara Finazzi, Gianni Tognoni, Alessandro Rambaldi
Lancet Haematology, 2021
Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis
Gabriella Galatà, Andrés C. García-Montero, Thomas Kristensen, Ahmed A.Z. Dawoud, Javier I. Muñoz-González, Manja Meggendorfer, Paola Guglielmelli, Yvette Hoade, Ivan Alvarez-Twose, Christian Gieger, Konstantin Strauch, Luigi Ferrucci, Toshiko Tanaka, Stefania Bandinelli, Theresia M. Schnurr, Torsten Haferlach, Sigurd Broesby-Olsen, Hanne Vestergaard, Michael Boe Møller, Carsten Bindslev-Jensen, Alessandro M. Vannucchi, Alberto Orfao, Deepti Radia, Andreas Reiter, Andrew J. Chase, Nicholas C.P. Cross, William J. Tapper
American Journal of Human Genetics, 2021
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
Tiziano Barbui, Valerio De Stefano, Alberto Alvarez-Larran, Alessandra Iurlo, Arianna Masciulli, Alessandra Carobbio, Arianna Ghirardi, Alberto Ferrari, Valeria Cancelli, Elena Maria Elli, Marcio Miguel Andrade-Campos, Mercedes Gasior Kabat, Jean-Jaques Kiladjian, Francesca Palandri, Giulia Benevolo, Valentin Garcia-Gutierrez, Maria Laura Fox, Maria Angeles Foncillas, Carmen Montoya Morcillo, Elisa Rumi, Santiago Osorio, Petros Papadopoulos, Massimiliano Bonifacio, Keina Susana Quiroz Cervantes, Miguel Sagues Serrano, Gonzalo Carreno-Tarragona, Marta Anna Sobas, Francesca Lunghi, Andrea Patriarca, Begoña Navas Elorza, Anna Angona, Elena Magro Mazo, Steffen Koschmieder, Giuseppe Carli, Beatriz Cuevas, Juan Carlos Hernandez-Boluda, Emma Lopez Abadia, Blanca Xicoy Cirici, Paola Guglielmelli, Marta Garrote, Daniele Cattaneo, Rosa Daffini, Fabrizio Cavalca, Beatriz Bellosillo, Lina Benajiba, Natalia Curto-Garcia, Marta Bellini, Silvia Betti, Claire Harrison, Alessandro Rambaldi, Alessandro Maria Vannucchi
Blood Cancer Journal, 2021
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
Tiziano Barbui, Alessandro Maria Vannucchi, Alberto Alvarez-Larran, Alessandra Iurlo, Arianna Masciulli, Alessandra Carobbio, Arianna Ghirardi, Alberto Ferrari, Giuseppe Rossi, Elena Elli, Marcio Miguel Andrade-Campos, Mercedes Gasior Kabat, Jean-Jaques Kiladjian, Francesca Palandri, Giulia Benevolo, Valentin Garcia-Gutierrez, Maria Laura Fox, Maria Angeles Foncillas, Carmen Montoya Morcillo, Elisa Rumi, Santiago Osorio, Petros Papadopoulos, Massimiliano Bonifacio, Keina Susana Quiroz Cervantes, Miguel Sagues Serrano, Gonzalo Carreno-Tarragona, Marta Anna Sobas, Francesca Lunghi, Andrea Patriarca, Begona Navas Elorza, Anna Angona, Elena Magro Mazo, Steffen Koschmieder, Marco Ruggeri, Beatriz Cuevas, Juan Carlos Hernandez-Boluda, Emma Lopez Abadia, Blanca Xicoy Cirici, Paola Guglielmelli, Marta Garrote, Daniele Cattaneo, Rosa Daffini, Fabrizio Cavalca, Beatriz Bellosillo, Lina Benajiba, Natalia Curto-Garcia, Marta Bellini, Silvia Betti, Valerio De Stefano, Claire Harrison, Alessandro Rambaldi
Leukemia, 2021
The MPL mutation
Paola Guglielmelli, Laura Calabresi
International Review of Cell and Molecular Biology, 2021
Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study
Vikas Gupta, Martin Griesshammer, Bruno Martino, Lynda Foltz, Renato Tavares, Haifa Kathrin Al-Ali, Pilar Giraldo, Paola Guglielmelli, Elza Lomaia, Catherine Bouard, Carole Paley, Ranjan Tiwari, Evren Zor, Pia Raanani
Leukemia and Lymphoma, 2021
The HScore for secondary hemophagocytic lymphohistiocytosis, calculated without a marrow biopsy, is consistently low in patients with COVID-19
Giuseppe G. Loscocco, Danilo Malandrino, Simone Barchiesi, Andrea Berni, Loredana Poggesi, Paola Guglielmelli, Alessandro M. Vannucchi
International Journal of Laboratory Hematology, 2020
A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease
Giuseppe G. Loscocco, Francesco Mannelli, Lara Mannelli, Federica Vergoni, Francesca Gesullo, Giada Rotunno, Paola Guglielmelli, Alessandro M. Vannucchi
American Journal of Hematology, 2020
Shared and Distinctive Ultrastructural Abnormalities Expressed by Megakaryocytes in Bone Marrow and Spleen From Patients With Myelofibrosis
Maria Zingariello, Vittorio Rosti, Alessandro M. Vannucchi, Paola Guglielmelli, Maria Mazzarini, Giovanni Barosi, Maria Luisa Genova, Anna Rita Migliaccio
Frontiers in Oncology, 2020
A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis
Alessandra Carobbio, Paola Guglielmelli, Elisa Rumi, Chiara Cavalloni, Valerio De Stefano, Silvia Betti, Alessandro Rambaldi, Maria Chiara Finazzi, Juergen Thiele, Alessandro M. Vannucchi, Ayalew Tefferi, Tiziano Barbui
Blood Cancer Journal, 2020
Genetic lesions disrupting calreticulin 3′-untranslated region in JAK2 mutation-negative polycythemia vera
Alberto Quattrocchi, Carlo Maiorca, Monia Billi, Simona Tomassini, Elisabetta De Marinis, Natalia Cenfra, Francesco Equitani, Martina Gentile, Alessia Ceccherelli, Cristina Banella, Sergio Mecarocci, Maria Cristina Scerpa, Stefania Pisanò, Annalisa Pacilli, Claudio Di Cristofano, Massimiliano Mancini, Paola Guglielmelli, Alessandro Maria Vannucchi, Nelida Noguera, Francesco Grignani, Giuseppe Cimino, Clara Nervi
American Journal of Hematology, 2020
RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features
Giacomo Coltro, Giada Rotunno, Lara Mannelli, Carmela Mannarelli, Sara Fiaccabrino, Simone Romagnoli, Niccolò Bartalucci, Enrica Ravenda, Eleonora Gelli, Emanuela Sant’Antonio, Mrinal M. Patnaik, Ayalew Tefferi, Alessandro M. Vannucchi, Paola Guglielmelli
Blood Advances, 2020
An agenda for future research projects in polycythemia vera and essential thrombocythemia
Tiziano Barbui, Alessandro Maria Vannucchi, Paola Guglielmelli, Valerio De Stefano, Alessandro Rambaldi
Haematologica, 2020
A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia
Bianca Rocca, Alberto Tosetto, Silvia Betti, Denise Soldati, Giovanna Petrucci, Elena Rossi, Andrea Timillero, Viviana Cavalca, Benedetta Porro, Alessandra Iurlo, Daniele Cattaneo, Cristina Bucelli, Alfredo Dragani, Mauro Di Ianni, Paola Ranalli, Francesca Palandri, Nicola Vianelli, Eloise Beggiato, Giuseppe Lanzarone, Marco Ruggeri, Giuseppe Carli, Elena Maria Elli, Monica Carpenedo, Maria Luigia Randi, Irene Bertozzi, Chiara Paoli, Giorgina Specchia, Alessandra Ricco, Alessandro Maria Vannucchi, Francesco Rodeghiero, Carlo Patrono, Valerio De Stefano
Blood, 2020
Polycythemia vera: the current status of preclinical models and therapeutic targets
Niccolò Bartalucci, Paola Guglielmelli, Alessandro M. Vannucchi
Expert Opinion on Therapeutic Targets, 2020
Current management strategies for polycythemia vera and essential thrombocythemia
Paola Guglielmelli, Alessandro M. Vannucchi
Blood Reviews, 2020
Thrombocytopenia in patients with myelofibrosis: management options in the era of JAK inhibitor therapy
Giulia Benevolo, Elena M. Elli, Paola Guglielmelli, Alessandra Ricco, Margherita Maffioli
Leukemia and Lymphoma, 2020
Drug-related cutaneous adverse events in philadelphia chromosome-negative myeloproliferative neoplasms: A literature review
Alessandra Malato, Elena Rossi, Giuseppe Alberto Palumbo, Paola Guglielmelli, Novella Pugliese
International Journal of Molecular Sciences, 2020
Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature
Giacomo Coltro, Francesco Mannelli, Federica Vergoni, Raffaella Santi, Daniela Massi, Luisa Margherita Siliani, Antonella Marzullo, Stefania Bonifacio, Elisabetta Pelo, Annalisa Pacilli, Chiara Paoli, Annalisa Franci, Laura Calabresi, Alberto Bosi, Alessandro Maria Vannucchi, Paola Guglielmelli
Clinical and Experimental Medicine, 2020
Stem cell transplant for the treatment of myelofibrosis
Lara Mannelli, Paola Guglielmelli, Alessandro M. Vannucchi
Expert Review of Hematology, 2020
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera
Ayalew Tefferi, Paola Guglielmelli, Terra L. Lasho, Giacomo Coltro, Christy M. Finke, Giuseppe G. Loscocco, Benedetta Sordi, Natasha Szuber, Giada Rotunno, Annalisa Pacilli, Curtis A. Hanson, Rhett P. Ketterling, Animesh Pardanani, Naseema Gangat, Alessandro M. Vannucchi
British Journal of Haematology, 2020
Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin
on behalf of MPN-K authors, Tiziano Barbui, Arianna Ghirardi, Alessandro Maria Vannucchi, Monia Marchetti, Valerio De Stefano
Leukemia, 2020
Second cancers in MPN: Survival analysis from an international study
Monia Marchetti, Arianna Ghirardi, Arianna Masciulli, Alessandra Carobbio, Francesca Palandri, Nicola Vianelli, Elena Rossi, Silvia Betti, Ambra Di Veroli, Alessandra Iurlo, Daniele Cattaneo, Guido Finazzi, Massimiliano Bonifacio, Luigi Scaffidi, Andrea Patriarca, Elisa Rumi, Ilaria Carola Casetti, Clemency Stephenson, Paola Guglielmelli, Elena Maria Elli, Miroslava Palova, Davide Rapezzi, Daniel Erez, Montse Gomez, Kai Wille, Manuel Perez‐Encinas, Francesca Lunghi, Anna Angona, Maria Laura Fox, Eloise Beggiato, Giulia Benevolo, Giuseppe Carli, Rossella Cacciola, Mary Frances McMullin, Alessia Tieghi, Valle Recasens, Susanne Isfort, Fabrizio Pane, Valerio De Stefano, Martin Griesshammer, Alberto Alvarez‐Larran, Alessandro Maria Vannucchi, Alessandro Rambaldi, Tiziano Barbui
American Journal of Hematology, 2020
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis
Paola Guglielmelli, Alessandra Carobbio, Elisa Rumi, Valerio De Stefano, Lara Mannelli, Francesco Mannelli, Giada Rotunno, Giacomo Coltro, Silvia Betti, Chiara Cavalloni, Maria Chiara Finazzi, Juergen Thiele, Mario Cazzola, Alessandro Maria Vannucchi, Tiziano Barbui
Blood Cancer Journal, 2020
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases
Emanuela Sant'Antonio, Paola Guglielmelli, Lisa Pieri, Massimo Primignani, Maria Luigia Randi, Claudia Santarossa, Elisa Rumi, Francisco Cervantes, Federica Delaini, Alessandra Carobbio, Silvia Betti, Elena Rossi, Noa Lavi, Claire N. Harrison, Natalia Curto‐Garcia, Heinz Gisslinger, Bettina Gisslinger, Giorgina Specchia, Alessandra Ricco, Nicola Vianelli, Nicola Polverelli, Maya Koren‐Michowitz, Marco Ruggeri, Francois Girodon, Martin Ellis, Alessandra Iurlo, Francesco Mannelli, Lara Mannelli, Benedetta Sordi, Giuseppe Gaetano Loscocco, Mario Cazzola, Valerio De Stefano, Tiziano Barbui, Ayalew Tefferi, Alessandro Maria Vannucchi
American Journal of Hematology, 2020
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: A case-control study
Valerio De Stefano, Arianna Ghirardi, Arianna Masciulli, Alessandra Carobbio, Francesca Palandri, Nicola Vianelli, Elena Rossi, Silvia Betti, Ambra Di Veroli, Alessandra Iurlo, Daniele Cattaneo, Guido Finazzi, Massimiliano Bonifacio, Luigi Scaffidi, Andrea Patriarca, Elisa Rumi, Ilaria Carola Casetti, Clemency Stephenson, Paola Guglielmelli, Elena Maria Elli, Miroslava Palova, Davide Rapezzi, Daniel Erez, Montse Gomez, Kai Wille, Manuel Perez-Encinas, Francesca Lunghi, Anna Angona, Maria Laura Fox, Eloise Beggiato, Giulia Benevolo, Giuseppe Carli, Rossella Cacciola, Mary Frances McMullin, Alessia Tieghi, Valle Recasens, Susanne Isfort, Monia Marchetti, Martin Griesshammer, Alberto Alvarez-Larran, Alessandro Maria Vannucchi, Alessandro Rambaldi, Tiziano Barbui
Blood, 2020
Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning
Jessica L. Bridgford, Su Min Lee, Christine M. M. Lee, Paola Guglielmelli, Elisa Rumi, Daniela Pietra, Stephen Wilcox, Yash Chhabra, Alan F. Rubin, Mario Cazzola, Alessandro M. Vannucchi, Andrew J. Brooks, Matthew E. Call, Melissa J. Call
Blood, 2020
Impact of mutational profile on the management of myeloproliferative neoplasms: A short review of the emerging data
Giuseppe G Loscocco, Paola Guglielmelli, Alessandro M Vannucchi
Oncotargets and Therapy, 2020
Essential thrombocythemia and acquired von willebrand syndrome: The shadowlands between thrombosis and bleeding
Hassan Awada, Maria Voso, Paola Guglielmelli, Carmelo Gurnari
Cancers, 2020
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms
Paola Guglielmelli, Annalisa Pacilli, Giacomo Coltro, Francesco Mannelli, Lara Mannelli, Elisa Contini, Giada Rotunno, Niccolò Bartalucci, Sara Fiaccabrino, Benedetta Sordi, Giuseppe Gaetano Loscocco, Chiara Paoli, Alessandro M. Vannucchi
American Journal of Hematology, 2020
Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice
Massimo Breccia, Claudia Baratè, Giulia Benevolo, Massimiliano Bonifacio, Elena Maria Elli, Paola Guglielmelli, Margherita Maffioli, Alessandra Malato, Francesco Mendicino, Giuseppe Alberto Palumbo, Novella Pugliese, Elena Rossi, Elisa Rumi, Emanuela Sant’Antonio, Alessandra Ricco, Mario Tiribelli, Francesca Palandri
Annals of Hematology, 2020
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group
Barbara Mora, Paola Guglielmelli, Elisa Rumi, Margherita Maffioli, Daniela Barraco, Alessandro Rambaldi, Marianna Caramella, Rami S. Komrokji, Jean‐Jacques Kiladjian, Jason Gotlib, Alessandra Iurlo, Francisco Cervantes, Timothy Devos, Francesca Palandri, Valerio De Stefano, Marco Ruggeri, Richard T. Silver, Francesco Albano, Giulia Benevolo, Chiara Cavalloni, Silvia Uccella, Raffaella Accetta, Claudia Siracusa, Stefania Agnoli, Michele Merli, Tiziano Barbui, Lorenza Bertù, Mario Cazzola, Alessandro M. Vannucchi, Francesco Passamonti
American Journal of Hematology, 2020
Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases
Elda Mimiola, Riccardo Bomben, Giovanna De Matteis, Omar Perbellini, Paola Guglielmelli, Massimiliano Bonifacio, Alice Parisi, Valter Gattei, Alberto Zamò, Francesco Mannelli, Andrés Celestino García Montero, Roberta Zanotti
Hematological Oncology, 2019
Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants
Simona Salati, Elena Genovese, Chiara Carretta, Roberta Zini, Niccolò Bartalucci, Zelia Prudente, Valentina Pennucci, Samantha Ruberti, Chiara Rossi, Sebastiano Rontauroli, Elena Enzo, Laura Calabresi, Manjola Balliu, Carmela Mannarelli, Elisa Bianchi, Paola Guglielmelli, Enrico Tagliafico, Alessandro M. Vannucchi, Rossella Manfredini
Scientific Reports, 2019
Nano-GLADIATOR: Real-time detection of copy number alterations from nanopore sequencing data
Alberto Magi, Davide Bolognini, Niccoló Bartalucci, Alessandra Mingrino, Roberto Semeraro, Luna Giovannini, Stefania Bonifacio, Daniela Parrini, Elisabetta Pelo, Francesco Mannelli, Paola Guglielmelli, Alessandro Maria Vannucchi
Bioinformatics, 2019
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative
Giuseppe G. Loscocco, Francesco Mannelli, Paola Guglielmelli, Chiara Paoli, Ilaria Marone, Rosalba Cucci, Giacomo Coltro, Benedetta Sordi, Francesco Albano, Massimo Breccia, Valerio De Stefano, Guido Finazzi, Alessandra Iurlo, Bruno Martino, Francesca Palandri, Francesco Passamonti, Sergio Siragusa, Lara Mannelli, Duccio Fantoni, Paola Fazi, Sergio Amadori, Marco Vignetti, Tiziano Barbui, Alessandro M. Vannucchi
American Journal of Hematology, 2019
Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis
Francesco Mannelli, Francesca Gesullo, Giada Rotunno, Annalisa Pacilli, Sara Bencini, Francesco Annunziato, Roberta Zanotti, Luigi Scaffidi, Fiorina Giona, Michelina Santopietro, Federica Grifoni, Lisa Pieri, Paola Guglielmelli, Alessandro M. Vannucchi
American Journal of Hematology, 2019
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study
Tiziano Barbui, Arianna Ghirardi, Arianna Masciulli, Alessandra Carobbio, Francesca Palandri, Nicola Vianelli, Valerio De Stefano, Silvia Betti, Ambra Di Veroli, Alessandra Iurlo, Daniele Cattaneo, Federica Delaini, Massimiliano Bonifacio, Luigi Scaffidi, Andrea Patriarca, Elisa Rumi, Ilaria Carola Casetti, Clemency Stephenson, Paola Guglielmelli, Elena Maria Elli, Miroslava Palova, Laura Bertolotti, Daniel Erez, Montse Gomez, Kai Wille, Manuel Perez-Encinas, Francesca Lunghi, Anna Angona, Maria Laura Fox, Eloise Beggiato, Giulia Benevolo, Giuseppe Carli, Rossella Cacciola, Mary Frances McMullin, Alessia Tieghi, Valle Recasens, Monia Marchetti, Martin Griesshammer, Alberto Alvarez-Larran, Alessandro Maria Vannucchi, Guido Finazzi
Leukemia, 2019
Spectrum of ASXL1 mutations in primary myelofibrosis: Prognostic impact of the ASXL1 p.G646Wfs∗12 mutation
Giada Rotunno, Carmela Mannarelli, Giada Brogi, Annalisa Pacilli, Francesca Gesullo, Francesco Mannelli, Sara Fiaccabrino, Benedetta Sordi, Chiara Paoli, Ilaria Marone, Elisa Rumi, Rossella Manfredini, Giovanni Barosi, Mario Cazzola, Alessandro M. Vannucchi, Paola Guglielmelli
Blood, 2019
The JAK2 46/1 (GGCC) MPN-predisposing haplotype: A risky haplotype, after all
Alessandro M. Vannucchi, Paola Guglielmelli
American Journal of Hematology, 2019
Validation of the Mayo alliance prognostic system for mastocytosis
Francesco Mannelli, Francesca Gesullo, Giada Rotunno, Annalisa Pacilli, Lisa Pieri, Paola Guglielmelli, Alessandro M. Vannucchi
Blood Cancer Journal, 2019
Long reads, short time: Feasibility of prenatal sample karyotyping by nanopore genome sequencing
Niccolò Bartalucci, Simone Romagnoli, Elisa Contini, Giuseppina Marseglia, Alberto Magi, Paola Guglielmelli, Elisabetta Pelo, Alessandro M Vannucchi
Clinical Chemistry, 2019
Circ RNAs are here to stay: A perspective on the MLL recombinome
Anna Dal Molin, Silvia Bresolin, Enrico Gaffo, Caterina Tretti, Elena Boldrin, Lueder H. Meyer, Paola Guglielmelli, Alessandro M. Vannucchi, Geertruij te Kronnie, Stefania Bortoluzzi
Frontiers in Genetics, 2019
Results from Harmony: An open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis
Simon T. Durrant, Arnon Nagler, Paola Guglielmelli, David Lavie, Philipp le Coutre, Heinz Gisslinger, Charles Chuah, Margherita Maffioli, Savita Bharathy, Tuochuan Dong, Monika Wroclawska, Joaquin Martinez Lopez
Haematologica, 2019
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients
Barbara Mora, Elisa Rumi, Paola Guglielmelli, Daniela Barraco, Margherita Maffioli, Alessandro Rambaldi, Marianna Caramella, Rami Komrokji, Jason Gotlib, Jean Jacques Kiladjian, Francisco Cervantes, Timothy Devos, Francesca Palandri, Valerio De Stefano, Marco Ruggeri, Richard T. Silver, Giulia Benevolo, Francesco Albano, Chiara Cavalloni, Daniela Pietra, Tiziano Barbui, Giada Rotunno, Mario Cazzola, Alessandro Maria Vannucchi, Toni Giorgino, Francesco Passamonti
Cancer Medicine, 2019
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
Annalisa Pacilli, Giada Rotunno, Carmela Mannarelli, Tiziana Fanelli, Alessandro Pancrazzi, Elisa Contini, Francesco Mannelli, Francesca Gesullo, Niccolò Bartalucci, Giuditta Corbizi Fattori, Chiara Paoli, Alessandro M. Vannucchi, Paola Guglielmelli
Blood Cancer Journal, 2018
Role of TGF-β1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis
Chiara Rossi, Roberta Zini, Sebastiano Rontauroli, Samantha Ruberti, Zelia Prudente, Greta Barbieri, Elisa Bianchi, Simona Salati, Elena Genovese, Niccolò Bartalucci, Paola Guglielmelli, Enrico Tagliafico, Vittorio Rosti, Giovanni Barosi, Alessandro M. Vannucchi, Rossella Manfredini, the AGIMM (AIRC‐Gruppo Italiano Malattie Mieloproliferative) investigators
Molecular Oncology, 2018
Mayo alliance prognostic system for mastocytosis: Clinical and hybrid clinical-molecular models
Animesh Pardanani, Sahrish Shah, Francesco Mannelli, Yoseph C. Elala, Paola Guglielmelli, Terra L. Lasho, Mrinal M. Patnaik, Naseema Gangat, Rhett P. Ketterling, Kaaren K. Reichard, Curtis A. Hanson, Alessandro M. Vannucchi, Ayalew Tefferi
Blood Advances, 2018
Classification and personalized prognosis in myeloproliferative neoplasms
Jacob Grinfeld, Jyoti Nangalia, E. Joanna Baxter, David C. Wedge, Nicos Angelopoulos, Robert Cantrill, Anna L. Godfrey, Elli Papaemmanuil, Gunes Gundem, Cathy MacLean, Julia Cook, Laura O’Neil, Sarah O’Meara, Jon W. Teague, Adam P. Butler, Charlie E. Massie, Nicholas Williams, Francesca L. Nice, Christen L. Andersen, Hans C. Hasselbalch, Paola Guglielmelli, Mary F. McMullin, Alessandro M. Vannucchi, Claire N. Harrison, Moritz Gerstung, Anthony R. Green, Peter J. Campbell
New England Journal of Medicine, 2018
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project
Daniela Barraco, Barbara Mora, Paola Guglielmelli, Elisa Rumi, Margherita Maffioli, Alessandro Rambaldi, Marianna Caramella, Rami Komrokji, Jason Gotlib, Jean Jacques Kiladjian, Francisco Cervantes, Timothy Devos, Francesca Palandri, Valerio De Stefano, Marco Ruggeri, Richard T. Silver, Giulia Benevolo, Francesco Albano, Michele Merli, Daniela Pietra, Tiziano Barbui, Giada Rotunno, Mario Cazzola, Toni Giorgino, Alessandro Maria Vannucchi, Francesco Passamonti
Blood Cancer Journal, 2018
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial
Martin Griesshammer, Guray Saydam, Francesca Palandri, Giulia Benevolo, Miklos Egyed, Jeannie Callum, Timothy Devos, Serdar Sivgin, Paola Guglielmelli, Caroline Bensasson, Mahmudul Khan, Julian Perez Ronco, Francesco Passamonti
Annals of Hematology, 2018
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC project
Barbara Mora, Toni Giorgino, Paola Guglielmelli, Elisa Rumi, Margherita Maffioli, Alessandro Rambaldi, Marianna Caramella, Rami Komrokji, Jason Gotlib, Jean Jacques Kiladjian, Francisco Cervantes, Timothy Devos, Francesca Palandri, Valerio De Stefano, Marco Ruggeri, Richard T. Silver, Giulia Benevolo, Francesco Albano, Chiara Cavalloni, Daniela Barraco, Michele Merli, Daniela Pietra, Rosario Casalone, Tiziano Barbui, Giada Rotunno, Mario Cazzola, Alessandro Maria Vannucchi, Francesco Passamonti
Haematologica, 2018
Myelofibrosis Treatment Algorithm 2018
Ayalew Tefferi, Paola Guglielmelli, Animesh Pardanani, Alessandro M. Vannucchi
Blood Cancer Journal, 2018
GIPSS: Genetically inspired prognostic scoring system for primary myelofibrosis
Ayalew Tefferi, Paola Guglielmelli, Maura Nicolosi, Francesco Mannelli, Mythri Mudireddy, Niccolo Bartalucci, Christy M. Finke, Terra L. Lasho, Curtis A. Hanson, Rhett P. Ketterling, Kebede H. Begna, Naseema Gangat, Animesh Pardanani, Alessandro M. Vannucchi
Leukemia, 2018
Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide
Claire N. Harrison, Martin Griesshammer, Carole Miller, Tamas Masszi, Francesco Passamonti, Pierre Zachee, Simon Durrant, Fabrizio Pane, Paola Guglielmelli, Srdan Verstovsek, Mark M. Jones, Deborah S. Hunter, William Sun, Jingjin Li, Mahmudul Khan, Dany Habr, Jean‐Jacques Kiladjian
British Journal of Haematology, 2018
MIPSS701 version 2.0: Mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis
Ayalew Tefferi, Paola Guglielmelli, Terra L. Lasho, Naseema Gangat, Rhett P. Ketterling, Animesh Pardanani, Alessandro M. Vannucchi
Journal of Clinical Oncology, 2018
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia
Barbara Mora, Toni Giorgino, Paola Guglielmelli, Elisa Rumi, Margherita Maffioli, Alessandro Rambaldi, Marianna Caramella, Rami Komrokji, Jason Gotlib, Jean Jacques Kiladjian, Francisco Cervantes, Timothy Devos, Francesca Palandri, Valerio De Stefano, Marco Ruggeri, Richard T. Silver, Giulia Benevolo, Francesco Albano, Chiara Cavalloni, Daniela Barraco, Daniela Pietra, Tiziano Barbui, Giada Rotunno, Alessandro Maria Vannucchi, Francesco Passamonti
Leukemia Research, 2018
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
Ayalew Tefferi, Mythri Mudireddy, Francesco Mannelli, Kebede H. Begna, Mrinal M. Patnaik, Curtis A. Hanson, Rhett P. Ketterling, Naseema Gangat, Meera Yogarajah, Valerio De Stefano, Francesco Passamonti, Vittorio Rosti, Maria Chiara Finazzi, Alessandro Rambaldi, Alberto Bosi, Paola Guglielmelli, Animesh Pardanani, Alessandro M. Vannucchi
Leukemia, 2018
The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells
Maria Antonietta Avanzini, Vittorio Abbonante, Paolo Catarsi, Irene Dambruoso, Melissa Mantelli, Valentina Poletto, Elisa Lenta, Paola Guglielmelli, Stefania Croce, Lorenzo Cobianchi, Basilio Jemos, Rita Campanelli, Elisa Bonetti, Christian Andrea Di Buduo, Silvia Salmoiraghi, Laura Villani, Margherita Massa, Marina Boni, Rita Zappatore, Alessandra Iurlo, Alessandro Rambaldi, Alessandro Maria Vannucchi, Paolo Bernasconi, Alessandra Balduini, Giovanni Barosi, Vittorio Rosti, on behalf of the AGIMM Investigators
American Journal of Hematology, 2018
JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease
Ayalew Tefferi, Sravanthi Lavu, Mythri Mudireddy, Terra L. Lasho, Christy M. Finke, Naseema Gangat, Animesh Pardanani, Curtis A. Hanson, Carmela Mannarelli, Paola Guglielmelli, Alessandro M. Vannucchi
American Journal of Hematology, 2018
Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies
Jean-Jacques Kiladjian, Paola Guglielmelli, Martin Griesshammer, Guray Saydam, Tamas Masszi, Simon Durrant, Francesco Passamonti, Mark Jones, Huiling Zhen, Jingjin Li, Brian Gadbaw, Julian Perez Ronco, Mahmudul Khan, Srdan Verstovsek
Annals of Hematology, 2018
Polycythemia vera and essential thrombocythemia: Algorithmic approach
Alessandro M. Vannucchi, Paola Guglielmelli, Ayalew Tefferi
Current Opinion in Hematology, 2018
Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients
Ayalew Tefferi, Maura Nicolosi, Mythri Mudireddy, Natasha Szuber, Christy M. Finke, Terra L. Lasho, Curtis A. Hanson, Rhett P. Ketterling, Animesh Pardanani, Naseema Gangat, Carmela Mannarelli, Tiziana Fanelli, Paola Guglielmelli, Alessandro M. Vannucchi
American Journal of Hematology, 2018
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms
Valerio De Stefano, Alessandra Carobbio, Vincenzo Di Lazzaro, Paola Guglielmelli, Alessandra Iurlo, Maria Chiara Finazzi, Elisa Rumi, Francisco Cervantes, Elena Maria Elli, Maria Luigia Randi, Martin Griesshammer, Francesca Palandri, Massimiliano Bonifacio, Juan-Carlos Hernandez-Boluda, Rossella Cacciola, Palova Miroslava, Giuseppe Carli, Eloise Beggiato, Martin H. Ellis, Caterina Musolino, Gianluca Gaidano, Davide Rapezzi, Alessia Tieghi, Francesca Lunghi, Giuseppe Gaetano Loscocco, Daniele Cattaneo, Agostino Cortelezzi, Silvia Betti, Elena Rossi, Guido Finazzi, Bruno Censori, Mario Cazzola, Marta Bellini, Eduardo Arellano-Rodrigo, Irene Bertozzi, Parvis Sadjadian, Nicola Vianelli, Luigi Scaffidi, Montse Gomez, Emma Cacciola, Alessandro M. Vannucchi, Tiziano Barbui
Blood Cancer Journal, 2018
Calreticulin Affects Hematopoietic Stem/Progenitor Cell Fate by Impacting Erythroid and Megakaryocytic Differentiation
Simona Salati, Zelia Prudente, Elena Genovese, Valentina Pennucci, Sebastiano Rontauroli, Niccolò Bartalucci, Carmela Mannarelli, Samantha Ruberti, Roberta Zini, Chiara Rossi, Elisa Bianchi, Paola Guglielmelli, Enrico Tagliafico, Alessandro M. Vannucchi, Rossella Manfredini, on behalf of the AGIMM (AIRC Gruppo
Stem Cells and Development, 2018
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
Tiziano Barbui, Jürgen Thiele, Heinz Gisslinger, Hans Michael Kvasnicka, Alessandro M. Vannucchi, Paola Guglielmelli, Attilio Orazi, Ayalew Tefferi
Blood Cancer Journal, 2018
Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib
Annalisa Pacilli, Tiziana Fanelli, Carmela Mannarelli, Giada Rotunno, Alessandro Pancrazzi, Alessandro Maria Vannucchi, Paola Guglielmelli
Hematological Oncology, 2018
MIPSS70: Mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis
Paola Guglielmelli, Terra L. Lasho, Giada Rotunno, Mythri Mudireddy, Carmela Mannarelli, Maura Nicolosi, Annalisa Pacilli, Animesh Pardanani, Elisa Rumi, Vittorio Rosti, Curtis A. Hanson, Francesco Mannelli, Rhett P. Ketterling, Naseema Gangat, Alessandro Rambaldi, Francesco Passamonti, Giovanni Barosi, Tiziano Barbui, Mario Cazzola, Alessandro M. Vannucchi, Ayalew Tefferi
Journal of Clinical Oncology, 2018
Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients
, S Ruberti, E Bianchi, P Guglielmelli, S Rontauroli, G Barbieri, L Tavernari, T Fanelli, R Norfo, V Pennucci, G Corbizi Fattori, C Mannarelli, N Bartalucci, B Mora, L Elli, M A Avanzini, C Rossi, S Salmoiraghi, R Zini, S Salati, Z Prudente, V Rosti, F Passamonti, A Rambaldi, S Ferrari, E Tagliafico, A M Vannucchi, R Manfredini
Leukemia, 2018
What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?
Alessandro M. Vannucchi, Paola Guglielmelli
Hematology, 2017
CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles
Roberta Zini, Paola Guglielmelli, Daniela Pietra, Elisa Rumi, Chiara Rossi, Sebastiano Rontauroli, Elena Genovese, Tiziana Fanelli, Laura Calabresi, Elisa Bianchi, Simona Salati, Mario Cazzola, Enrico Tagliafico, Alessandro M. Vannucchi, Rossella Manfredini, on behalf of the AGIMM (AIRC Gruppo Italiano Malattie Mieloproliferative) investigators
Blood Cancer Journal, 2017
Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients
Ayalew Tefferi, Silvia Betti, Daniela Barraco, Mythri Mudireddy, Sahrish Shah, Curtis A. Hanson, Rhett P. Ketterling, Animesh Pardanani, Naseema Gangat, Giacomo Coltro, Paola Guglielmelli, Alessandro M. Vannucchi
American Journal of Hematology, 2017
The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey
Claire N. Harrison, Steffen Koschmieder, Lynda Foltz, Paola Guglielmelli, Tina Flindt, Michael Koehler, Jonathan Mathias, Norio Komatsu, Robert N. Boothroyd, Amber Spierer, Julian Perez Ronco, Gavin Taylor-Stokes, John Waller, Ruben A. Mesa
Annals of Hematology, 2017
Traffic lights for ruxolitinib
Alessandro M. Vannucchi, Paola Guglielmelli
Blood, 2017
A life-threatening ruxolitinib discontinuation syndrome
Giacomo Coltro, Francesco Mannelli, Paola Guglielmelli, Annalisa Pacilli, Alberto Bosi, Alessandro Maria Vannucchi
American Journal of Hematology, 2017
Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders–A consensus project of the Italian Society of Hematology
Paola Guglielmelli, Daniela Pietra, Fabrizio Pane, Alessandro Pancrazzi, Mario Cazzola, Alessandro M. Vannucchi, Sante Tura, Giovanni Barosi
Leukemia Research, 2017
Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study
Alessandro Maria Vannucchi, Srdan Verstovsek, Paola Guglielmelli, Martin Griesshammer, Timothy C. Burn, Ahmad Naim, Dilan Paranagama, Mahtab Marker, Brian Gadbaw, Jean-Jacques Kiladjian
Annals of Hematology, 2017
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis
Paola Guglielmelli, Annalisa Pacilli, Giada Rotunno, Elisa Rumi, Vittorio Rosti, Federica Delaini, Margherita Maffioli, Tiziana Fanelli, Alessandro Pancrazzi, Daniela Pietra, Silvia Salmoiraghi, Carmela Mannarelli, Annalisa Franci, Chiara Paoli, Alessandro Rambaldi, Francesco Passamonti, Giovanni Barosi, Tiziano Barbui, Mario Cazzola, Alessandro M. Vannucchi
Blood, 2017
Driver mutations' effect in secondary myelofibrosis: An international multicenter study based on 781 patients
F Passamonti, B Mora, T Giorgino, P Guglielmelli, M Cazzola, M Maffioli, A Rambaldi, M Caramella, R Komrokji, J Gotlib, J J Kiladjian, F Cervantes, T Devos, F Palandri, V De Stefano, M Ruggeri, R Silver, G Benevolo, F Albano, D Caramazza, E Rumi, M Merli, D Pietra, R Casalone, T Barbui, L Pieri, A M Vannucchi
Leukemia, 2017
Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
Federico Lussana, Alessandra Carobbio, Silvia Salmoiraghi, Paola Guglielmelli, Alessandro Maria Vannucchi, Barbara Bottazzi, Roberto Leone, Alberto Mantovani, Tiziano Barbui, Alessandro Rambaldi
Journal of Hematology and Oncology, 2017
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms
Lisa Pieri, Chiara Paoli, Umberto Arena, Fabio Marra, Fabio Mori, Mery Zucchini, Stefano Colagrande, Alessandro Castellani, Arianna Masciulli, Vittorio Rosti, Valerio De Stefano, Silvia Betti, Guido Finazzi, Maria Luisa Ferrari, Elisa Rumi, Marco Ruggeri, Ilaria Nichele, Paola Guglielmelli, Rajmonda Fjerza, Carmela Mannarelli, Tiziana Fanelli, Lucia Merli, Giuditta Corbizi Fattori, Margherita Massa, Giuseppe Cimino, Alessandro Rambaldi, Giovanni Barosi, Mario Cazzola, Tiziano Barbui, Alessandro M. Vannucchi
American Journal of Hematology, 2017
Role of miR-34a-5p in hematopoietic progenitor cells proliferation and fate decision: Novel insights into the pathogenesis of primary myelofibrosis
Elisa Bianchi, Samantha Ruberti, Sebastiano Rontauroli, Paola Guglielmelli, Simona Salati, Chiara Rossi, Roberta Zini, Enrico Tagliafico, Alessandro Vannucchi, Rossella Manfredini
International Journal of Molecular Sciences, 2017
Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/ CIP2A axis
Niccolò Bartalucci, Laura Calabresi, Manjola Balliu, Serena Martinelli, Maria Caterina Rossi, Jean Luc Villeval, Francesco Annunziato, Paola Guglielmelli, Alessandro M. Vannucchi
Oncotarget, 2017
miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6
Sebastiano Rontauroli, Ruggiero Norfo, Valentina Pennucci, Roberta Zini, Samantha Ruberti, Elisa Bianchi, Simona Salati, Zelia Prudente, Chiara Rossi, Vittorio Rosti, Paola Guglielmelli, Giovanni Barosi, Alessandro Vannucchi, Enrico Tagliafico, Rossella Manfredini
Oncotarget, 2017
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
F Passamonti, T Giorgino, B Mora, P Guglielmelli, E Rumi, M Maffioli, A Rambaldi, M Caramella, R Komrokji, J Gotlib, J J Kiladjian, F Cervantes, T Devos, F Palandri, V De Stefano, M Ruggeri, R T Silver, G Benevolo, F Albano, D Caramazza, M Merli, D Pietra, R Casalone, G Rotunno, T Barbui, M Cazzola, A M Vannucchi
Leukemia, 2017
Splanchnic vein thrombosis in myeloproliferative neoplasms: Risk factors for recurrences in a cohort of 181 patients
V De Stefano, A M Vannucchi, M Ruggeri, F Cervantes, A Alvarez-Larrán, A Iurlo, M L Randi, L Pieri, E Rossi, P Guglielmelli, S Betti, E Elli, M C Finazzi, G Finazzi, E Zetterberg, N Vianelli, G Gaidano, I Nichele, D Cattaneo, M Palova, M H Ellis, E Cacciola, A Tieghi, J C Hernandez-Boluda, E Pungolino, G Specchia, D Rapezzi, A Forcina, C Musolino, A Carobbio, M Griesshammer, T Barbui
Blood Cancer Journal, 2016
The prognostic impact of bone marrow fibrosis in primary myelofibrosis
Paola Guglielmelli, Alessandro M. Vannucchi, on behalf of AGIMM Investigators
American Journal of Hematology, 2016
Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms
Giuseppe Gaetano Loscocco, Carmela Mannarelli, Annalisa Pacilli, Tiziana Fanelli, Giada Rotunno, Francesca Gesullo, Giuditta Corbizi‐Fattori, Alessandro Maria Vannucchi, Paola Guglielmelli
American Journal of Hematology, 2016
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients
Paola Guglielmelli, Giada Rotunno, Annalisa Pacilli, Elisa Rumi, Vittorio Rosti, Federica Delaini, Margherita Maffioli, Tiziana Fanelli, Alessandro Pancrazzi, Lisa Pieri, Rajmonda Fjerza, Daniela Pietra, Daniela Cilloni, Emanuela Sant'Antonio, Silvia Salmoiraghi, Francesco Passamonti, Alessandro Rambaldi, Giovanni Barosi, Tiziano Barbui, Mario Cazzola, Alessandro M. Vannucchi
American Journal of Hematology, 2016
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation
A. Alvarez-Larran, A. Pereira, P. Guglielmelli, J. C. Hernandez-Boluda, E. Arellano-Rodrigo, F. Ferrer-Marin, A. Samah, M. Griesshammer, A. Kerguelen, B. Andreasson, C. Burgaleta, J. Schwarz, V. Garcia-Gutierrez, R. Ayala, P. Barba, M. T. Gomez-Casares, C. Paoli, B. Drexler, S. Zweegman, M. F. McMullin, J. Samuelsson, C. Harrison, F. Cervantes, A. M. Vannucchi, C. Besses
Haematologica, 2016
Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis
Takafumi Shimizu, Lucia Kubovcakova, Ronny Nienhold, Jakub Zmajkovic, Sara C. Meyer, Hui Hao-Shen, Florian Geier, Stephan Dirnhofer, Paola Guglielmelli, Alessandro M. Vannucchi, Jelena D. Milosevic Feenstra, Robert Kralovics, Stuart H. Orkin, Radek C. Skoda
Journal of Experimental Medicine, 2016
Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group
Giada Rotunno, Annalisa Pacilli, Valentina Artusi, Elisa Rumi, Margherita Maffioli, Federica Delaini, Giada Brogi, Tiziana Fanelli, Alessandro Pancrazzi, Daniela Pietra, Isabella Bernardis, Clara Belotti, Lisa Pieri, Emanuela Sant'Antonio, Silvia Salmoiraghi, Daniela Cilloni, Alessandro Rambaldi, Francesco Passamonti, Tiziano Barbui, Rossella Manfredini, Mario Cazzola, Enrico Tagliafico, Alessandro M. Vannucchi, Paola Guglielmelli
American Journal of Hematology, 2016
Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis
Paola Guglielmelli, Giada Rotunno, Costanza Bogani, Carmela Mannarelli, Laura Giunti, Aldesia Provenzano, Sabrina Giglio, Matthew Squires, Viktoriya Stalbovskaya, Prashanth Gopalakrishna, Alessandro M. Vannucchi, the COMFORT‐II Investigators
British Journal of Haematology, 2016
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis
Rita Campanelli, Gabriela Fois, Paolo Catarsi, Valentina Poletto, Laura Villani, Benedetta Gaia Erba, Luigi Maddaluno, Basilio Jemos, Silvia Salmoiraghi, Paola Guglielmelli, Vittorio Abbonante, Christian Andrea Di Buduo, Alessandra Balduini, Alessandra Iurlo, Giovanni Barosi, Vittorio Rosti, Margherita Massa, AGIMM Investigators
Plos One, 2016
Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosis
Simona Salati, Roberta Zini, Simona Nuzzo, Paola Guglielmelli, Valentina Pennucci, Zelia Prudente, Samantha Ruberti, Sebastiano Rontauroli, Ruggiero Norfo, Elisa Bianchi, Costanza Bogani, Giada Rotunno, Tiziana Fanelli, Carmela Mannarelli, Vittorio Rosti, Silvia Salmoiraghi, Daniela Pietra, Sergio Ferrari, Giovanni Barosi, Alessandro Rambaldi, Mario Cazzola, Silvio Bicciato, Enrico Tagliafico, Alessandro M. Vannucchi, Rossella Manfredini, and
International Journal of Cancer, 2016
The newly diagnosed patient with polycythemia vera
Alessandro M. Vannucchi, Paola Guglielmelli
Managing Myeloproliferative Neoplasms A Case Based Approach, 2016
STAT1 activation in association with JAK2 exon 12 mutations
A. L. Godfrey, E. Chen, C. E. Massie, Y. Silber, F. Pagano, B. Bellosillo, P. Guglielmelli, C. N. Harrison, J. T. Reilly, F. Stegelmann, F. Bijou, E. Lippert, J.-M. Boiron, K. Dohner, A. M. Vannucchi, C. Besses, A. R. Green
Haematologica, 2016
A data-driven network model of primary myelofibrosis: Transcriptional and post-transcriptional alterations in CD34+ cells
E Calura, S Pizzini, A Bisognin, A Coppe, G Sales, E Gaffo, T Fanelli, C Mannarelli, R Zini, R Norfo, V Pennucci, R Manfredini, C Romualdi, P Guglielmelli, A M Vannucchi, S Bortoluzzi, on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators
Blood Cancer Journal, 2016
What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?
Paola Guglielmelli, Giada Rotunno, Annalisa Pacilli, Alessandro Maria Vannucchi
Current Hematologic Malignancy Reports, 2015
Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis
P Guglielmelli, G Rotunno, T Fanelli, A Pacilli, G Brogi, L Calabresi, A Pancrazzi, A M Vannucchi, on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM)
Blood Cancer Journal, 2015
Small RNA sequencing uncovers new miRNAs and moRNAs differentially expressed in normal and primary myelofibrosis CD34+ Cells
Paola Guglielmelli, Andrea Bisognin, Claudia Saccoman, Carmela Mannarelli, Alessandro Coppe, Alessandro M. Vannucchi, Stefania Bortoluzzi
Plos One, 2015
Profound parental bias associated with chromosome 14 acquired uniparental disomy indicates targeting of an imprinted locus
A Chase, W Leung, W Tapper, A V Jones, L Knoops, C Rasi, L A Forsberg, P Guglielmelli, K Zoi, V Hall, L Chiecchio, L Eder-Azanza, C Bryant, L Lannfelt, L Docherty, H E White, J Score, D J G Mackay, A M Vannucchi, J P Dumanski, N C P Cross
Leukemia, 2015
Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis
Christophe Martinaud, Christophe Desterke, Johanna Konopacki, Alessandro M. Vannucchi, Lisa Pieri, Paola Guglielmelli, Brigitte Dupriez, Jean-Christophe Ianotto, Laetitia Boutin, Jean-Jacques Lataillade, Marie-Caroline Le Bousse-Kerdilès
Genomics Data, 2015
CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis
M C Finazzi, A Carobbio, F Cervantes, I M Isola, A M Vannucchi, P Guglielmelli, A Rambaldi, G Finazzi, G Barosi, T Barbui
Leukemia, 2015
Prognostic relevance of mutations in myelofi-brosis
GUGLIELMELLI, PAOLA, ROTUNNO, GIADA, PACILLI, ANNALISA, Mannarelii, Carmela
Novel Insights into Myelofibrosis Pathophysiology and Treatment, 2015
Rationale for combination therapies in myelofi-brosis
Alessandro M Vannucchi, Niccolò Bartalucci, Lisa Pieri, Paola Guglielmelli
Novel Insights into Myelofibrosis Pathophysiology and Treatment, 2015
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms
William Tapper, Amy V. Jones, Robert Kralovics, Ashot S. Harutyunyan, Katerina Zoi, William Leung, Anna L. Godfrey, Paola Guglielmelli, Alison Callaway, Daniel Ward, Paula Aranaz, Helen E. White, Katherine Waghorn, Feng Lin, Andrew Chase, E. Joanna Baxter, Cathy Maclean, Jyoti Nangalia, Edwin Chen, Paul Evans, Michael Short, Andrew Jack, Louise Wallis, David Oscier, Andrew S. Duncombe, Anna Schuh, Adam J. Mead, Michael Griffiths, Joanne Ewing, Rosemary E. Gale, Susanne Schnittger, Torsten Haferlach, Frank Stegelmann, Konstanze Döhner, Harald Grallert, Konstantin Strauch, Toshiko Tanaka, Stefania Bandinelli, Andreas Giannopoulos, Lisa Pieri, Carmela Mannarelli, Heinz Gisslinger, Giovanni Barosi, Mario Cazzola, Andreas Reiter, Claire Harrison, Peter Campbell, Anthony R. Green, Alessandro Vannucchi, Nicholas C.P. Cross
Nature Communications, 2015
Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: Results of preclinical studies and a phase II clinical trial
A Pardanani, A Tefferi, P Guglielmelli, C Bogani, N Bartalucci, J Rodríguez, S Extremera, I Pérez, V Alfaro, A M Vannucchi
Blood Cancer Journal, 2015
Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis
Angela Rago, Roberto Latagliata, Marco Montanaro, Enrico Montefusco, Alessandro Andriani, Sabrina Leonetti Crescenzi, Sergio Mecarocci, Francesca Spirito, Antonio Spadea, Umberto Recine, Laura Cicconi, Giuseppe Avvisati, Michele Cedrone, Massimo Breccia, Raffaele Porrini, Nicoletta Villivà, Cinzia De Gregoris, Giuliana Alimena, Enzo D’Arcangelo, Paola Guglielmelli, Francesco Lo-Coco, Alessandro Vannucchi, Giuseppe Cimino
Leukemia Research, 2015
Effect of mutation order on myeloproliferative neoplasms
Christina A. Ortmann, David G. Kent, Jyoti Nangalia, Yvonne Silber, David C. Wedge, Jacob Grinfeld, E. Joanna Baxter, Charles E. Massie, Elli Papaemmanuil, Suraj Menon, Anna L. Godfrey, Danai Dimitropoulou, Paola Guglielmelli, Beatriz Bellosillo, Carles Besses, Konstanze Döhner, Claire N. Harrison, George S. Vassiliou, Alessandro Vannucchi, Peter J. Campbell, Anthony R. Green
New England Journal of Medicine, 2015
Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations
Valentina Pennucci, Roberta Zini, Ruggiero Norfo, Paola Guglielmelli, Elisa Bianchi, Simona Salati, Giorgia Sacchi, Zelia Prudente, Elena Tenedini, Samantha Ruberti, Chiara Paoli, Tiziana Fanelli, Carmela Mannarelli, Enrico Tagliafico, Sergio Ferrari, Alessandro M. Vannucchi, Rossella Manfredini, and
Leukemia and Lymphoma, 2015
Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia
Lisa Pieri, Paola Guglielmelli, Alessandro M. Vannucchi
American Journal of Hematology, 2015
JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib
Lisa Pieri, Alessandro Pancrazzi, Annalisa Pacilli, Claudia Rabuzzi, Giada Rotunno, Tiziana Fanelli, Paola Guglielmelli, Rajmonda Fjerza, Chiara Paoli, Srdan Verstovsek, Alessandro M. Vannucchi
Blood, 2015
Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia
Guido Finazzi, Alessandra Carobbio, Paola Guglielmelli, Chiara Cavalloni, Silvia Salmoiraghi, Alessandro M. Vannucchi, Mario Cazzola, Francesco Passamonti, Alessandro Rambaldi, Tiziano Barbui
Blood, 2014
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
Ayalew Tefferi, Paola Guglielmelli, Dirk R. Larson, Christy Finke, Emnet A. Wassie, Lisa Pieri, Naseema Gangat, Rajmonda Fjerza, Alem A. Belachew, Terra L. Lasho, Rhett P. Ketterling, Curtis A. Hanson, Alessandro Rambaldi, Guido Finazzi, Juergen Thiele, Tiziano Barbui, Animesh Pardanani, Alessandro M. Vannucchi
Blood, 2014
miRNA-mRNA integrative analysis in primary myelofibrosis CD34+cells: Role of miR-155/JARID2 axis in abnormal megakaryopoiesis
Ruggiero Norfo, Roberta Zini, Valentina Pennucci, Elisa Bianchi, Simona Salati, Paola Guglielmelli, Costanza Bogani, Tiziana Fanelli, Carmela Mannarelli, Vittorio Rosti, Daniela Pietra, Silvia Salmoiraghi, Andrea Bisognin, Samantha Ruberti, Sebastiano Rontauroli, Giorgia Sacchi, Zelia Prudente, Giovanni Barosi, Mario Cazzola, Alessandro Rambaldi, Stefania Bortoluzzi, Sergio Ferrari, Enrico Tagliafico, Alessandro M. Vannucchi, Rossella Manfredini
Blood, 2014
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
Elisa Rumi, Daniela Pietra, Cristiana Pascutto, Paola Guglielmelli, Alejandra Martínez-Trillos, Ilaria Casetti, Dolors Colomer, Lisa Pieri, Marta Pratcorona, Giada Rotunno, Emanuela Sant’Antonio, Marta Bellini, Chiara Cavalloni, Carmela Mannarelli, Chiara Milanesi, Emanuela Boveri, Virginia Ferretti, Cesare Astori, Vittorio Rosti, Francisco Cervantes, Giovanni Barosi, Alessandro M. Vannucchi, Mario Cazzola
Blood, 2014
Essential Thrombocytosis
Paola Guglielmelli, Alessandro M. Vannucchi
Cancer Consult Expertise for Clinical Practice, 2014
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study
Paola Guglielmelli, Flavia Biamonte, Giada Rotunno, Valentina Artusi, Lucia Artuso, Isabella Bernardis, Elena Tenedini, Lisa Pieri, Chiara Paoli, Carmela Mannarelli, Rajmonda Fjerza, Elisa Rumi, Viktoriya Stalbovskaya, Matthew Squires, Mario Cazzola, Rossella Manfredini, Claire Harrison, Enrico Tagliafico, Alessandro M. Vannucchi
Blood, 2014
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia
Giada Rotunno, Carmela Mannarelli, Paola Guglielmelli, Annalisa Pacilli, Alessandro Pancrazzi, Lisa Pieri, Tiziana Fanelli, Alberto Bosi, Alessandro M. Vannucchi
Blood, 2014
Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms
Giada Rotunno, Paola Guglielmelli, Flavia Biamonte, Elisa Rumi, Mario Cazzola, Alessandro M. Vannucchi
Annals of Hematology, 2014
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
Srdan Verstovsek, Francesco Passamonti, Alessandro Rambaldi, Giovanni Barosi, Peter J. Rosen, Elisa Rumi, Elisabetta Gattoni, Lisa Pieri, Paola Guglielmelli, Chiara Elena, Shui He, Nancy Contel, Bijoyesh Mookerjee, Victor Sandor, Mario Cazzola, Hagop M. Kantarjian, Tiziano Barbui, Alessandro M. Vannucchi
Cancer, 2014
Givinostat for the treatment of polycythemia vera
Lisa Pieri, Paola Guglielmelli, Guido Finazzi, Alessandro M Vannucchi
Expert Opinion on Orphan Drugs, 2014
CALR mutations in myeloproliferative neoplasms: Hidden behind the reticulum
Paola Guglielmelli, Jyoti Nangalia, Anthony R. Green, Alessandro M. Vannucchi
American Journal of Hematology, 2014
Calreticulin: A new horizon for the testing and treatment of myeloproliferative neoplasms
Paola Guglielmelli, Niccolò Bartalucci, Giada Rotunno, Alessandro M Vannucchi
Expert Review of Hematology, 2014
Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients
Tiziano Barbui, Jürgen Thiele, Alessandra Carobbio, Paola Guglielmelli, Alessandro Rambaldi, Alessandro M. Vannucchi, Ayalew Tefferi
American Journal of Hematology, 2014
CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: An international study of 570 patients
A Tefferi, P Guglielmelli, T L Lasho, G Rotunno, C Finke, C Mannarelli, A A Belachew, A Pancrazzi, E A Wassie, R P Ketterling, C A Hanson, A Pardanani, A M Vannucchi
Leukemia, 2014
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: Pathogenetic insight and diagnostic value
on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators, A M Vannucchi, G Rotunno, N Bartalucci, G Raugei, V Carrai, M Balliu, C Mannarelli, A Pacilli, L Calabresi, R Fjerza, L Pieri, A Bosi, R Manfredini, P Guglielmelli
Leukemia, 2014
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients
Ayalew Tefferi, Emnet A. Wassie, Paola Guglielmelli, Naseema Gangat, Alem A. Belachew, Terra L. Lasho, Christy Finke, Rhett P. Ketterling, Curtis A. Hanson, Animesh Pardanani, Alexandra P. Wolanskyj, Margherita Maffioli, Rosario Casalone, Annalisa Pacilli, Alessandro M. Vannucchi, Francesco Passamonti
American Journal of Hematology, 2014
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms
on behalf of AGIMM investigators, E Tenedini, I Bernardis, V Artusi, L Artuso, E Roncaglia, P Guglielmelli, L Pieri, C Bogani, F Biamonte, G Rotunno, C Mannarelli, E Bianchi, A Pancrazzi, T Fanelli, G Malagoli Tagliazucchi, S Ferrari, R Manfredini, A M Vannucchi, E Tagliafico
Leukemia, 2014
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: An international study of 797 patients
P Guglielmelli, T L Lasho, G Rotunno, J Score, C Mannarelli, A Pancrazzi, F Biamonte, A Pardanani, K Zoi, A Reiter, A Duncombe, T Fanelli, D Pietra, E Rumi, C Finke, N Gangat, R P Ketterling, R A Knudson, C A Hanson, A Bosi, A Pereira, R Manfredini, F Cervantes, G Barosi, M Cazzola, N C P Cross, A M Vannucchi, A Tefferi
Leukemia, 2014
Struggling with myelofibrosis-associated anemia
Paola Guglielmelli, Alessandro M. Vannucchi
Leukemia Research, 2013
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2
Thorsten Klampfl, Jelena D. Milosevic, Ana Puda, Andreas Schönegger, Klaudia Bagienski, Tiina Berg, Ashot S. Harutyunyan, Bettina Gisslinger, Elisa Rumi, Luca Malcovati, Daniela Pietra, Chiara Elena, Matteo Giovanni Della Porta, Lisa Pieri, Paola Guglielmelli, Christoph Bock, Michael Doubek, Dana Dvorakova, Nada Suvajdzic, Dragica Tomin, Natasa Tosic, Zdenek Racil, Michael Steurer, Sonja Pavlovic, Alessandro M. Vannucchi, Mario Cazzola, Heinz Gisslinger, Robert Kralovics
Plos One, 2013
Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis
T Barbui, A Carobbio, G Finazzi, P Guglielmelli, S Salmoiraghi, V Rosti, A Rambaldi, A M Vannucchi, G Barosi
Leukemia, 2013
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: A joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study
J V Jovanovic, A Ivey, A M Vannucchi, E Lippert, E Oppliger Leibundgut, B Cassinat, N Pallisgaard, N Maroc, S Hermouet, G Nickless, P Guglielmelli, B A van der Reijden, J H Jansen, T Alpermann, S Schnittger, A Bench, K Tobal, B Wilkins, K Cuthill, D McLornan, K Yeoman, S Akiki, J Bryon, S Jeffries, A Jones, M J Percy, S Schwemmers, A Gruender, T W Kelley, S Reading, A Pancrazzi, M F McMullin, H L Pahl, N C P Cross, C N Harrison, J T Prchal, C Chomienne, J J Kiladjian, T Barbui, D Grimwade
Leukemia, 2013
Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis
A. Spolverini, L. Pieri, P. Guglielmelli, A. Pancrazzi, T. Fanelli, C. Paoli, A. Bosi, I. Nichele, M. Ruggeri, A. M. Vannucchi
Haematologica, 2013
Mutations and prognosis in primary myelofibrosis
A M Vannucchi, T L Lasho, P Guglielmelli, F Biamonte, A Pardanani, A Pereira, C Finke, J Score, N Gangat, C Mannarelli, R P Ketterling, G Rotunno, R A Knudson, M C Susini, R R Laborde, A Spolverini, A Pancrazzi, L Pieri, R Manfredini, E Tagliafico, R Zini, A Jones, K Zoi, A Reiter, A Duncombe, D Pietra, E Rumi, F Cervantes, G Barosi, M Cazzola, N C P Cross, A Tefferi
Leukemia, 2013
The ERCC2 Gln/Gln polymorphism at codon 751 is not associated with leukaemic transformation in primary myelofibrosis
Maria C. Susini, Paola Guglielmelli, Ambra Spolverini, Flavia Biamonte, Carmela Mannarelli, Giovanni Barosi, Katerina Zoi, Andreas Reiter, Andrew Duncombe, Francisco Cervantes, Mario Cazzola, Nick Cross, Alessandro M. Vannucchi, the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators
British Journal of Haematology, 2013
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms
Elisa Rumi, Daniela Pietra, Paola Guglielmelli, Roberta Bordoni, Ilaria Casetti, Chiara Milanesi, Emanuela Sant’Antonio, Virginia Ferretti, Alessandro Pancrazzi, Giada Rotunno, Marco Severgnini, Alessandro Pietrelli, Cesare Astori, Elena Fugazza, Cristiana Pascutto, Emanuela Boveri, Francesco Passamonti, Gianluca De Bellis, Alessandro Vannucchi, Mario Cazzola
Blood, 2013
JAK2 mutation-related disease and thrombosis
Paola Guglielmelli, Alessandro Vannucchi
Seminars in Thrombosis and Hemostasis, 2013
mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms
Costanza Bogani, Niccolò Bartalucci, Serena Martinelli, Lorenzo Tozzi, Paola Guglielmelli, Alberto Bosi, Alessandro M. Vannucchi, Associazione Italiana per la Ricerca sul Cancro AGIMM Gruppo Italiano Malattie Mieloproliferative
Plos One, 2013
Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation
Vittorio Rosti, Laura Villani, Roberta Riboni, Valentina Poletto, Elisa Bonetti, Lorenzo Tozzi, Gaetano Bergamaschi, Paolo Catarsi, Elena Dallera, Francesca Novara, Margherita Massa, Rita Campanelli, Gabriela Fois, Benedetta Peruzzi, Marco Lucioni, Paola Guglielmelli, Alessandro Pancrazzi, Giacomo Fiandrino, Orsetta Zuffardi, Umberto Magrini, Marco Paulli, Alessandro M. Vannucchi, Giovanni Barosi
Blood, 2013
Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms
Niccolò Bartalucci, Paola Guglielmelli, Alessandro M. Vannucchi
Clinical Lymphoma Myeloma and Leukemia, 2013
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2
J. Nangalia, C.E. Massie, E.J. Baxter, F.L. Nice, G. Gundem, D.C. Wedge, E. Avezov, J. Li, K. Kollmann, D.G. Kent, A. Aziz, A.L. Godfrey, J. Hinton, I. Martincorena, P. Van Loo, A.V. Jones, P. Guglielmelli, P. Tarpey, H.P. Harding, J.D. Fitzpatrick, C.T. Goudie, C.A. Ortmann, S.J. Loughran, K. Raine, D.R. Jones, A.P. Butler, J.W. Teague, S. O'Meara, S. McLaren, M. Bianchi, Y. Silber, D. Dimitropoulou, D. Bloxham, L. Mudie, M. Maddison, B. Robinson, C. Keohane, C. Maclean, K. Hill, K. Orchard, S. Tauro, M.-Q. Du, M. Greaves, D. Bowen, B.J.P. Huntly, C.N. Harrison, N.C.P. Cross, D. Ron, A.M. Vannucchi, E. Papaemmanuil, P.J. Campbell, A.R. Green
New England Journal of Medicine, 2013
Molecular genetics in diagnosis and prognosis of philadelphia chromosome negative myeloproliferative neoplasms molecular genetics in MPNS
Onkologie, 2012
JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone
Anna L. Godfrey, Edwin Chen, Francesca Pagano, Christina A. Ortmann, Yvonne Silber, Beatriz Bellosillo, Paola Guglielmelli, Claire N. Harrison, John T. Reilly, Frank Stegelmann, Fontanet Bijou, Eric Lippert, Mary F. McMullin, Jean-Michel Boiron, Konstanze Döhner, Alessandro M. Vannucchi, Carlos Besses, Peter J. Campbell, Anthony R. Green
Blood, 2012
Improving survival trends in primary myelofibrosis: An international study
Francisco Cervantes, Brigitte Dupriez, Francesco Passamonti, Alessandro M. Vannucchi, Enrica Morra, John T. Reilly, Jean-Loup Demory, Elisa Rumi, Paola Guglielmelli, Elisa Roncoroni, Ayalew Tefferi, Arturo Pereira
Journal of Clinical Oncology, 2012
BCR-ABL1-negative chronic myeloid neoplasms: An update on management techniques
Alessandro M Vannucchi, Lisa Pieri, Maria Chiara Susini, Paola Guglielmelli
Future Oncology, 2012
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post-ASH symposium
Omar Abdel‐Wahab, Animesh Pardanani, Olivier A. Bernard, Guido Finazzi, John D. Crispino, Heinz Gisslinger, Robert Kralovics, Olatoyosi Odenike, Kapil Bhalla, Vikas Gupta, Giovanni Barosi, Jason Gotlib, Paola Guglielmelli, Jean‐Jacques Kiladjian, Pierre Noel, Mario Cazzola, Alessandro M. Vannucchi, Ronald Hoffman, Tiziano Barbui, Juergen Thiele, Richard A. Van Etten, Tariq Mughal, Ayalew Tefferi
American Journal of Hematology, 2012
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN
Elisabetta Antonioli, Paola Guglielmelli, Lisa Pieri, MariaChiara Finazzi, Elisa Rumi, Vincenzo Martinelli, Nicola Vianelli, Maria Luigia Randi, Irene Bertozzi, Valerio De Stefano, Tommaso Za, Elena Rossi, Marco Ruggeri, Elena Elli, Rossella Cacciola, Emma Cacciola, Enrico Pogliani, Francesco Rodeghiero, Michele Baccarani, Francesco Passamonti, Guido Finazzi, Alessandro Rambaldi, Alberto Bosi, Mario Cazzola, Tiziano Barbui, Alessandro M. Vannucchi, On behalf of the AGIMM Investigators
American Journal of Hematology, 2012
Risk of second cancers in chronic myeloproliferative neoplasms
Maria Chiara Susini, Giovanna Masala, Elisabetta Antonioli, Lisa Pieri, Paola Guglielmelli, Domenico Palli, Alberto Bosi, Alessandro M. Vannucchi
Blood, 2012
Characterization and discovery of novel miRNAs and moRNAs in JAK2V617F-mutated SET2 cells
Stefania Bortoluzzi, Andrea Bisognin, Marta Biasiolo, Paola Guglielmelli, Flavia Biamonte, Ruggiero Norfo, Rossella Manfredini, Alessandro M. Vannucchi
Blood, 2012
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies
Ana Puda, Jelena D. Milosevic, Tiina Berg, Thorsten Klampfl, Ashot S. Harutyunyan, Bettina Gisslinger, Elisa Rumi, Daniela Pietra, Luca Malcovati, Chiara Elena, Michael Doubek, Michael Steurer, Natasa Tosic, Sonja Pavlovic, Paola Guglielmelli, Lisa Pieri, Alessandro M. Vannucchi, Heinz Gisslinger, Mario Cazzola, Robert Kralovics
American Journal of Hematology, 2012
Does the nasogastric tube has a role in elective colo-rectal surgery?
Il Giornale Di Chirurgia, 2012
EZH2 mutational status predicts poor survival in myelofibrosis
Paola Guglielmelli, Flavia Biamonte, Joannah Score, Claire Hidalgo-Curtis, Francisco Cervantes, Margherita Maffioli, Tiziana Fanelli, Thomas Ernst, Nils Winkelman, Amy V. Jones, Katerina Zoi, Andreas Reiter, Andrew Duncombe, Laura Villani, Alberto Bosi, Giovanni Barosi, Nicholas C. P. Cross, Alessandro M. Vannucchi
Blood, 2011
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
Paola Guglielmelli, Giovanni Barosi, Alessandro Rambaldi, Roberto Marchioli, Arianna Masciulli, Lorenzo Tozzi, Flavia Biamonte, Niccolò Bartalucci, Elisabetta Gattoni, Maria Letizia Lupo, Guido Finazzi, Alessandro Pancrazzi, Elisabetta Antonioli, Maria Chiara Susini, Lisa Pieri, Elisa Malevolti, Emilio Usala, Ubaldo Occhini, Alberto Grossi, Silvia Caglio, Simona Paratore, Alberto Bosi, Tiziano Barbui, Alessandro M. Vannucchi, on behalf of the AIRC-Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators
Blood, 2011
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression
Thorsten Klampfl, Ashot Harutyunyan, Tiina Berg, Bettina Gisslinger, Martin Schalling, Klaudia Bagienski, Damla Olcaydu, Francesco Passamonti, Elisa Rumi, Daniela Pietra, Roland Jäger, Lisa Pieri, Paola Guglielmelli, Ilaria Iacobucci, Giovanni Martinelli, Mario Cazzola, Alessandro M. Vannucchi, Heinz Gisslinger, Robert Kralovics
Blood, 2011
Overexpression of microRNA-16-2 contributes to the abnormal erythropoiesis in polycythemia vera
Paola Guglielmelli, Lorenzo Tozzi, Costanza Bogani, Ilaria Iacobucci, Vanessa Ponziani, Giovanni Martinelli, Alberto Bosi, Alessandro M. Vannucchi
Blood, 2011
FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis
Christophe Desterke, Chrystele Bilhou-Nabéra, Bernadette Guerton, Christophe Martinaud, Carole Tonetti, Denis Clay, Paola Guglielmelli, Alessandro Vannucchi, Dominique Bordessoule, Hans Hasselbalch, Brigitte Dupriez, Nassima Benzoubir, Marie-Françoise Bourgeade, Olivier Pierre-Louis, Vladimir Lazar, William Vainchenker, Annelise Bennaceur-Griscelli, Heinz Gisslinger, Stéphane Giraudier, Marie-Caroline Le Bousse-Kerdilès
Cancer Research, 2011
JAK2 allele burden in the myeloproliferative neoplasms: Effects on phenotype, prognosis and change with treatment
Alessandro M. Vannucchi, Lisa Pieri, Paola Guglielmelli
Therapeutic Advances in Hematology, 2011
Primary myelofibrosis with or without mutant MPL: Comparison of survival and clinical features involving 603 patients
A Pardanani, P Guglielmelli, T L Lasho, A Pancrazzi, C M Finke, A M Vannucchi, A Tefferi
Leukemia, 2011
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera different role of C-reactive protein and pentraxin 3
T. Barbui, A. Carobbio, G. Finazzi, A. M. Vannucchi, G. Barosi, E. Antonioli, P. Guglielmelli, A. Pancrazzi, S. Salmoiraghi, P. Zilio, C. Ottomano, R. Marchioli, I. Cuccovillo, B. Bottazzi, A. Mantovani, A. Rambaldi, on behalf of the AGIMM, IIC Investigators
Haematologica, 2011
High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis
Vittorio Rosti, Elisa Bonetti, Gaetano Bergamaschi, Rita Campanelli, Paola Guglielmelli, Marcello Maestri, Umberto Magrini, Margherita Massa, Carmine Tinelli, Gianluca Viarengo, Laura Villani, Massimo Primignani, Alessandro M. Vannucchi, Francesco Frassoni, Giovanni Barosi, on behalf of the AGIMM Investigators
Plos One, 2010
Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms
P. A. Beer, C. A. Ortmann, F. Stegelmann, P. Guglielmelli, J. T. Reilly, T. S. Larsen, H. C. Hasselbalch, A. M. Vannucchi, P. Moller, K. Dohner, A. R. Green
Haematologica, 2010
Advances in understanding and management of polycythemia vera
Alessandro M Vannucchi, Paola Guglielmelli
Current Opinion in Oncology, 2010
Hydroxyurea does not appreciably reduce JAK2 v617F allele burden in patients with polycythemia vera or essential thrombocythemia
E. Antonioli, A. Carobbio, L. Pieri, A. Pancrazzi, P. Guglielmelli, F. Delaini, V. Ponziani, N. Bartalucci, L. Tozzi, A. Bosi, A. Rambaldi, T. Barbui, A. M. Vannucchi
Haematologica, 2010
Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition
Giovanni Barosi, Elisabetta Gattoni, Paola Guglielmelli, Rita Campanelli, Fabio Facchetti, Simona Fisogni, Judith Goldberg, Roberto Marchioli, Ronald Hoffman, Alessandro M. Vannucchi
American Journal of Hematology, 2010
A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms
Alessandro Rambaldi, Chiara Maria Dellacasa, Guido Finazzi, Alessandra Carobbio, Maria Luisa Ferrari, Paola Guglielmelli, Elisabetta Gattoni, Silvia Salmoiraghi, Maria Chiara Finazzi, Silvia Di Tollo, Carmine D’Urzo, Alessandro M. Vannucchi, Giovanni Barosi, Tiziano Barbui
British Journal of Haematology, 2010
A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Francesco Passamonti, Francisco Cervantes, Alessandro Maria Vannucchi, Enrica Morra, Elisa Rumi, Arturo Pereira, Paola Guglielmelli, Ester Pungolino, Marianna Caramella, Margherita Maffioli, Cristiana Pascutto, Mario Lazzarino, Mario Cazzola, Ayalew Tefferi
Blood, 2010
Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms
Paola Guglielmelli, Alessandro M Vannucchi
F1000 Medicine Reports, 2010
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia
Valerio De Stefano, Tommaso Za, Elena Rossi, Alessandro M. Vannucchi, Marco Ruggeri, Elena Elli, Caterina Micò, Alessia Tieghi, Rossella R. Cacciola, Cristina Santoro, Giancarla Gerli, Paola Guglielmelli, Lisa Pieri, Francesca Scognamiglio, Francesco Rodeghiero, Enrico M. Pogliani, Guido Finazzi, Luigi Gugliotta, Giuseppe Leone, Tiziano Barbui
American Journal of Hematology, 2010
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation
for the GIMEMA Chronic Myeloproliferative Neoplasms Working Party, Valerio De Stefano, Tommaso Za, Elena Rossi, Alessandro M. Vannucchi, Marco Ruggeri, Elena Elli, Caterina Micò, Alessia Tieghi, Rossella R. Cacciola, Cristina Santoro, Nicola Vianelli, Paola Guglielmelli, Lisa Pieri, Francesca Scognamiglio, Emma Cacciola, Francesco Rodeghiero, Enrico M. Pogliani, Guido Finazzi, Luigi Gugliotta, Giuseppe Leone, Tiziano Barbui
Annals of Hematology, 2010
Thrombosis in primary myelofibrosis: Incidence and risk factors
Tiziano Barbui, Alessandra Carobbio, Francisco Cervantes, Alessandro M. Vannucchi, Paola Guglielmelli, Elisabetta Antonioli, Alberto Alvarez-Larrán, Alessandro Rambaldi, Guido Finazzi, Giovanni Barosi
Blood, 2010
Chronic myeloproliferative neoplasms: A collaborative approach
Lisa Pieri, Paola Guglielmelli, Alessandro Maria Vannucchi
Mediterranean Journal of Hematology and Infectious Diseases, 2010
CXCR4-independent rescue of the myeloproliferative defect of the Gata1 low myelofibrosis mouse model by aplidin®
Maria Verrucci, Alessandro Pancrazzi, Miguel Aracil, Fabrizio Martelli, Paola Guglielmelli, Maria Zingariello, Barbara Ghinassi, Emanuela D'Amore, José Jimeno, Alessandro M. Vannucchi, Anna Rita Migliaccio
Journal of Cellular Physiology, 2010
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis
P Guglielmelli, F Biamonte, A Spolverini, L Pieri, A Isgrò, E Antonioli, A Pancrazzi, A Bosi, G Barosi, A M Vannucchi
Leukemia, 2010
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
A Tefferi, T L Lasho, O Abdel-Wahab, P Guglielmelli, J Patel, D Caramazza, L Pieri, C M Finke, O Kilpivaara, M Wadleigh, M Mai, R F McClure, D G Gilliland, R L Levine, A Pardanani, A M Vannucchi
Leukemia, 2010
Treatment options for essential thrombocythemia and polycythemia vera
Alessandro M Vannucchi, Paola Guglielmelli, Lisa Pieri, Elisabetta Antonioli, Alberto Bosi
Expert Review of Hematology, 2009
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera
L. Pieri, C. Bogani, P. Guglielmelli, M. Zingariello, R. A. Rana, N. Bartalucci, A. Bosi, A. M. Vannucchi
Haematologica, 2009
JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera
Alessandra Carobbio, Guido Finazzi, Elisabetta Antonioli, Paola Guglielmelli, Alessandro M. Vannucchi, Chiara M. Dellacasa, Silvia Salmoiraghi, Federica Delaini, Alessandro Rambaldi, Tiziano Barbui
Experimental Hematology, 2009
Epigenetic therapy in myeloproliferative neoplasms: Evidence and perspectives
Alessandro M. Vannucchi, Paola Guglielmelli, Alessandro Rambaldi, Costanza Bogani, Tiziano Barbui
Journal of Cellular and Molecular Medicine, 2009
JAK2V617F mutation screening in patients with retinal vein thrombosis or recurrent fetal loss
Paola Guglielmelli, Cinzia Fatini, Meri Lenti, Alberto Bosi, Alessandro M. Vannucchi
Thrombosis Research, 2009
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms
Alessandro M. Vannucchi, Giovanna Masala, Elisabetta Antonioli, Maria Chiara Susini, Paola Guglielmelli, Lisa Pieri, Laura Maggi, Saverio Caini, Domenico Palli, Costanza Bogani, Vanessa Ponziani, Alessandro Pancrazzi, Francesco Annunziato, Alberto Bosi
Cancer Epidemiology Biomarkers and Prevention, 2009
Advances in understanding and management of myeloproliferative neoplasms
A. M. Vannucchi, P. Guglielmelli, A. Tefferi
CA Cancer Journal for Clinicians, 2009
JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis
P. Guglielmelli, G. Barosi, L. Pieri, E. Antonioli, A. Bosi, A. M. Vannucchi
Haematologica, 2009
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele
Paola Guglielmelli, Giovanni Barosi, Giorgina Specchia, Alessandro Rambaldi, Francesco Lo Coco, Elisabetta Antonioli, Lisa Pieri, Alessandro Pancrazzi, Vanessa Ponziani, Federica Delaini, Giovanni Longo, Emanuele Ammatuna, Vincenzo Liso, Alberto Bosi, Tiziano Barbui, Alessandro M. Vannucchi
Blood, 2009
Animal models of myelofibrosis
Alessandro M. Vannucchi, Jean-Luc Villeval, Orianne Wagner-Ballon, Paola Guglielmelli, Anna Rita Migliaccio
Source Book of Models for Biomedical Research, 2008
Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia
Alessandra Carobbio, Guido Finazzi, Elisabetta Antonioli, Paola Guglielmelli, Alessandro M. Vannucchi, Federica Delaini, Vittoria Guerini, Marco Ruggeri, Francesco Rodeghiero, Alessandro Rambaldi, Tiziano Barbui
Blood, 2008
Leukocytosis and risk stratification assessment in essential thrombocythemia
Alessandra Carobbio, Elisabetta Antonioli, Paola Guglielmelli, Alessandro M. Vannucchi, Federica Delaini, Vittoria Guerini, Guido Finazzi, Alessandro Rambaldi, Tiziano Barbui
Journal of Clinical Oncology, 2008
Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis
Costanza Bogani, Vanessa Ponziani, Paola Guglielmelli, Cristophe Desterke, Vittorio Rosti, Alberto Bosi, Marie-Caroline Le Bousse-Kerdilès, Giovanni Barosi, Alessandro M. Vannucchi
Stem Cells, 2008
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
Alessandro M. Vannucchi, Elisabetta Antonioli, Paola Guglielmelli, Alessandro Pancrazzi, Vittoria Guerini, Giovanni Barosi, Marco Ruggeri, Giorgina Specchia, Francesco Lo-Coco, Federica Delaini, Laura Villani, Silvia Finotto, Emanuele Ammatuna, Renato Alterini, Valentina Carrai, Gloria Capaccioli, Simonetta Di Lollo, Vincenzo Liso, Alessandro Rambaldi, Alberto Bosi, Tiziano Barbui
Blood, 2008
Molecular pathophysiology of Philaielphia-negative myeloproliferative disorders: Beyond JAK2 and MPL mutations
A. M. Vannucchi, P. Guglielmelli
Haematologica, 2008
Mesenchymal stem cells from JAK2V617F mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele
Lisa Pieri, Paola Guglielmelli, Costanza Bogani, Alberto Bosi, Alessandro M. Vannucchi
Leukemia Research, 2008
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: Incidence, risk factors, and effect of treatments
V. De Stefano, T. Za, E. Rossi, A. M. Vannucchi, M. Ruggeri, E. Elli, C. Mico, A. Tieghi, R. R. Cacciola, C. Santoro, G. Gerli, N. Vianelli, P. Guglielmelli, L. Pieri, F. Scognamiglio, F. Rodeghiero, E. M. Pogliani, G. Finazzi, L. Gugliotta, R. Marchioli, G. Leone, T. Barbui, for the GIMEMA CMD-Working Party
Haematologica, 2008
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: A critical reappraisal
A M Vannucchi, E Antonioli, P Guglielmelli, A Pardanani, A Tefferi
Leukemia, 2008
A sensitive detection method for WPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction
Alessandro Pancrazzi, Paola Guglielmelli, Vanessa Ponziani, Gaetano Bergamaschi, Alberto Bosi, Giovanni Barosi, Alessandro M. Vannucchi
Journal of Molecular Diagnostics, 2008
No role for CXCL12-G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia [16]
V Ponziani, F Mannelli, N Bartalucci, G Gianfaldoni, F Leoni, E Antonioli, P Guglielmelli, S Ciolli, A Bosi, A M Vannucchi
Leukemia, 2008
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia
E. Antonioli, P. Guglielmelli, G. Poli, C. Bogani, A. Pancrazzi, G. Longo, V. Ponziani, L. Tozzi, L. Pieri, V. Santini, A. Bosi, A. M. Vannucchi, for the Myeloproliferative Disorders Research Consortium (MPD-RC)
Haematologica, 2008
Polycythemia vera following autologous transplantation for AML: Insights on the kinetics of JAK2V617F clonal dominance
Elisabetta Antonioli, Paola Guglielmelli, Giada Poli, Valeria Santini, Alberto Bosi, Alessandro M. Vannucchi
Blood, 2007
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis
Giovanni Barosi, Gaetano Bergamaschi, Monia Marchetti, Alessandro M. Vannucchi, Paola Guglielmelli, Elisabetta Antonioli, Margherita Massa, Vittorio Rosti, Rita Campanelli, Laura Villani, Gianluca Viarengo, Elisabetta Gattoni, Giancarla Gerli, Giorgina Specchia, Carmine Tinelli, Alessandro Rambaldi, Tiziano Barbui
Blood, 2007
Significance of CTLA-4 and CD14 genetic polymorphisms in clinical outcome after allogeneic stem cell transplantation [3]
A M Vannucchi, S Guidi, P Guglielmelli, S Glinz, L Lombardini, A Busca, F Locatelli, A M Dall'Omo, A Bosi
Bone Marrow Transplantation, 2007
Insights into JAK2-V617F mutation in CML
Monica Bocchia, Alessandro M Vannucchi, Alessandro Gozzetti, Paola Guglielmelli, Giada Poli, Rosaria Crupi, Marzia Defina, Alberto Bosi, Lauria Francesco
Lancet Oncology, 2007
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia
Alessandro M. Vannucchi, Elisabetta Antonioli, Paola Guglielmelli, Alessandro Rambaldi, Giovanni Barosi, Roberto Marchioli, Rosa Maria Marfisi, Guido Finazzi, Vittoria Guerini, Fabrizio Fabris, Maria Luigia Randi, Valerio De Stefano, Sabrina Caberlon, Agostino Tafuri, Marco Ruggeri, Giorgina Specchia, Vincenzo Liso, Edoardo Rossi, Enrico Pogliani, Luigi Gugliotta, Alberto Bosi, Tiziano Barbui
Blood, 2007
Anaemia characterises patients with myelofibrosis harbouring Mpl W515L/K mutation
Paola Guglielmelli, Alessandro Pancrazzi, Gaetano Bergamaschi, Vittorio Rosti, Laura Villani, Elisabetta Antonioli, Alberto Bosi, Giovanni Barosi, Alessandro M. Vannucchi, for the GIMEMA‐Italian Registry of Myelofibrosis, the MPD Research Consortium, Chicago, IL, USA
British Journal of Haematology, 2007
B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis
C. Bogani, P. Guglielmelli, E. Antonioli, A. Pancrazzi, A. Bosi, A. M. Vannucchi
Haematologica, 2007
Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden
A M Vannucchi, E Antonioli, P Guglielmelli, G Longo, A Pancrazzi, V Ponziani, C Bogani, P R Ferrini, A Rambaldi, V Guerini, A Bosi, T Barbui, for the MPD Research Consortium
Leukemia, 2007
MicroRNA expression profile in granulocytes from primary myelofibrosis patients
Paola Guglielmelli, Lorenzo Tozzi, Alessandro Pancrazzi, Costanza Bogani, Elisabetta Antonioli, Vanessa Ponziani, Giada Poli, Roberta Zini, Sergio Ferrari, Rossella Manfredini, Alberto Bosi, Alessandro M. Vannucchi
Experimental Hematology, 2007
Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1)
Paola Guglielmelli, Roberta Zini, Costanza Bogani, Simona Salati, Alessandro Pancrazzi, Elisa Bianchi, Francesco Mannelli, Sergio Ferrari, Marie-Caroline Le Bousse-Kerdilès, Alberto Bosi, Giovanni Barosi, Anna Rita Migliaccio, Rossella Manfredini, Alessandro M. Vannucchi
Stem Cells, 2007
The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia
Vittorio Rosti, Margherita Massa, Alessandro M. Vannucchi, Gaetano Bergamaschi, Rita Campanelli, Alessandro Pecci, Gianluca Viarengo, Valentina Meli, Monia Marchetti, Paola Guglielmelli, Edward Bruno, Mingjiang Xu, Ronald Hoffman, Giovanni Barosi
Blood Cells Molecules and Diseases, 2007
Inconsistencies in the association between the JAK2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases [2]
Alessandro M. Vannucchi, Paola Guglielmelli, Elisabetta Antonioli, Silvia Mappa, Alessandro Pancrazzi, Costanza Bogani, Vanessa Ponziani, Alberto Bosi
British Journal of Haematology, 2006
Differential amplification of murine bipotent megakaryocytic/erythroid progenitor and precursor cells during recovery from acute and chronic erythroid stress
Massimo Sanchez, Irving L. Weissman, Maria Pallavicini, Mauro Valeri, Paola Guglielmelli, Alessandro Maria Vannucchi, Giovanni Migliaccio, Anna Rita Migliaccio
Stem Cells, 2006
A quantitative assay for JAK2V617F mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis
A M Vannucchi, A Pancrazzi, C Bogani, E Antonioli, P Guglielmelli
Leukemia, 2006
The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients [18]
V Ponziani, G Gianfaldoni, F Mannelli, F Leoni, S Ciolli, P Guglielmelli, E Antonioli, G Longo, A Bosi, A M Vannucchi
Leukemia, 2006
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia [7]
E Antonioli, P Guglielmelli, A Pancrazzi, C Bogani, M Verrucci, V Ponziani, G Longo, A Bosi, A M Vannucchi
Leukemia, 2005
Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis
Alessandro M. Vannucchi, Alessandro Pancrazzi, Paola Guglielmelli, Simonetta Di Lollo, Costanza Bogani, Gianna Baroni, Lucia Bianchi, Anna Rita Migliaccio, Alberto Bosi, Francesco Paoletti
American Journal of Pathology, 2005
PRV-1, erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia
Alessandro M. Vannucchi, Alberto Grossi, Alessandro Pancrazzi, Elisabetta Antonioli, Paola Guglielmelli, Francesca Balestri, Monica Biscardi, Simona Bulgarelli, Giovanni Longo, Claudio Graziano, Luigi Gugliotta, Alberto Bosi
British Journal of Haematology, 2004

Paola Guglielmelli

RESEARCH INTERESTS

Scopus Publications

RECENT SCHOLAR PUBLICATIONS

MOST CITED SCHOLAR PUBLICATIONS